

# Adriaan A Voors

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4989388/publications.pdf>

Version: 2024-02-01

576  
papers

73,249  
citations

1163

111  
h-index

693

253  
g-index

607  
all docs

607  
docs citations

607  
times ranked

46215  
citing authors

#	ARTICLE	IF	CITATIONS
1	2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal, 2016, 37, 2129-2200.	1.0	13,008
2	2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Journal of Heart Failure, 2016, 18, 891-975.	2.9	5,272
3	ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. European Heart Journal, 2012, 33, 1787-1847.	1.0	5,233
4	ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. European Journal of Heart Failure, 2012, 14, 803-869.	2.9	2,307
5	Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. New England Journal of Medicine, 2021, 384, 117-128.	13.9	1,080
6	The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet, The, 2012, 380, 1387-1395.	6.3	990
7	How to diagnose heart failure with preserved ejection fraction: the HFAâ€PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). European Heart Journal, 2019, 40, 3297-3317.	1.0	944
8	Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet, The, 2013, 381, 29-39.	6.3	810
9	Increased Central Venous Pressure Is Associated With Impaired Renal Function and Mortality in a Broad Spectrum of Patients With Cardiovascular Disease. Journal of the American College of Cardiology, 2009, 53, 582-588.	1.2	796
10	Angiotensinâ€converting enzyme 2 (<sc>ACE2</sc>), <sc>SARSâ€CoV</sc>â€2 and the pathophysiology of coronavirus disease 2019 (<sc>COVID</sc>â€19). Journal of Pathology, 2020, 251, 228-248.	2.1	791
11	Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. New England Journal of Medicine, 2020, 382, 1883-1893.	13.9	753
12	Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis. European Heart Journal, 2014, 35, 455-469.	1.0	747
13	EUR<i>Observational</i> Research Programme: regional differences and 1â€year followâ€up results of the Heart Failure Pilot Survey (ESCâ€HF Pilot). European Journal of Heart Failure, 2013, 15, 808-817.	2.9	645
14	Impaired Systolic Function by Strain Imaging in Heart Failure With Preserved Ejection Fraction. Journal of the American College of Cardiology, 2014, 63, 447-456.	1.2	591
15	Outcome of Pregnancy in Women With Congenital Heart Disease. Journal of the American College of Cardiology, 2007, 49, 2303-2311.	1.2	545
16	Predictors of pregnancy complications in women with congenital heart disease. European Heart Journal, 2010, 31, 2124-2132.	1.0	538
17	Worsening Renal Function and Prognosis in Heart Failure: Systematic Review and Meta-Analysis. Journal of Cardiac Failure, 2007, 13, 599-608.	0.7	527
18	Mitochondrial function as a therapeutic target in heart failure. Nature Reviews Cardiology, 2017, 14, 238-250.	6.1	525

#	ARTICLE	IF	CITATIONS
19	Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. <i>Annals of Medicine</i> , 2011, 43, 60-68.	1.5	506
20	Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2019, 21, 1169-1186.	2.9	490
21	Effects of Fosinopril and Pravastatin on Cardiovascular Events in Subjects With Microalbuminuria. <i>Circulation</i> , 2004, 110, 2809-2816.	1.6	489
22	Rolofylline, an Adenosine A <sub>1</sub> Receptor Antagonist, in Acute Heart Failure. <i>New England Journal of Medicine</i> , 2010, 363, 1419-1428.	13.9	473
23	Incidence and epidemiology of new onset heart failure with preserved vs. reduced ejection fraction in a community-based cohort: 11-year follow-up of PREVEND. <i>European Heart Journal</i> , 2013, 34, 1424-1431.	1.0	451
24	Galectin-3: a novel mediator of heart failure development and progression. <i>European Journal of Heart Failure</i> , 2009, 11, 811-817.	2.9	434
25	Noncardiac Comorbidities in Heart Failure With Reduced Versus Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2014, 64, 2281-2293.	1.2	424
26	Treating oxidative stress in heart failure: past, present and future. <i>European Journal of Heart Failure</i> , 2019, 21, 425-435.	2.9	407
27	Sex differences in heart failure. <i>European Heart Journal</i> , 2019, 40, 3859-3868c.	1.0	406
28	Effect of Serelaxin on Cardiac, Renal, and Hepatic Biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) Development Program. <i>Journal of the American College of Cardiology</i> , 2013, 61, 196-206.	1.2	397
29	Decreased cardiac output, venous congestion and the association with renal impairment in patients with cardiac dysfunction. <i>European Journal of Heart Failure</i> , 2007, 9, 872-878.	2.9	393
30	Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study. <i>Lancet</i> , The, 2009, 373, 1429-1439.	6.3	387
31	Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin-angiotensin-aldosterone inhibitors. <i>European Heart Journal</i> , 2020, 41, 1810-1817.	1.0	381
32	Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure. <i>New England Journal of Medicine</i> , 2021, 384, 105-116.	13.9	381
33	Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial. <i>Lancet</i> , The, 2016, 387, 1178-1186.	6.3	373
34	Comorbidities in patients with heart failure: an analysis of the European Heart Failure Pilot Survey. <i>European Journal of Heart Failure</i> , 2014, 16, 103-111.	2.9	355
35	B-Type Natriuretic Peptide and Prognosis in Heart Failure Patients With Preserved and Reduced Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2013, 61, 1498-1506.	1.2	352
36	Risk stratification for sudden cardiac death: current status and challenges for the future. <i>European Heart Journal</i> , 2014, 35, 1642-1651.	1.0	341

#	ARTICLE	IF	CITATIONS
37	The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. <i>Nature Medicine</i> , 2022, 28, 568-574.	15.2	341
38	EURObservational Research Programme: The Heart Failure Pilot Survey (ESC-HF Pilot). <i>European Journal of Heart Failure</i> , 2010, 12, 1076-1084.	2.9	340
39	Heart Failure With Preserved Ejection Fraction and Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2016, 68, 2217-2228.	1.2	292
40	Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Chronic Heart Failure and Iron Deficiency. <i>Circulation</i> , 2017, 136, 1374-1383.	1.6	289
41	Drawbacks and Prognostic Value of Formulas Estimating Renal Function in Patients With Chronic Heart Failure and Systolic Dysfunction. <i>Circulation</i> , 2006, 114, 1572-1580.	1.6	277
42	Diuretic response in acute heart failure: clinical characteristics and prognostic significance. <i>European Heart Journal</i> , 2014, 35, 1284-1293.	1.0	276
43	Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial. <i>European Heart Journal</i> , 2015, 36, 2565-2573.	1.0	274
44	A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease. <i>European Heart Journal</i> , 2016, 37, 2105-2114.	1.0	274
45	Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF). <i>European Journal of Heart Failure</i> , 2020, 22, 713-722.	2.9	260
46	Telomere Length of Circulating Leukocytes Is Decreased in Patients With Chronic Heart Failure. <i>Journal of the American College of Cardiology</i> , 2007, 49, 1459-1464.	1.2	257
47	Heart failure with preserved ejection fraction: from mechanisms to therapies. <i>European Heart Journal</i> , 2018, 39, 2780-2792.	1.0	250
48	Connecting heart failure with preserved ejection fraction and renal dysfunction: the role of endothelial dysfunction and inflammation. <i>European Journal of Heart Failure</i> , 2016, 18, 588-598.	2.9	242
49	Factors Influencing the Predictive Power of Models for Predicting Mortality and/or Heart Failure Hospitalization in Patients With Heart Failure. <i>JACC: Heart Failure</i> , 2014, 2, 429-436.	1.9	241
50	MicroRNAs in heart failure: from biomarker to target for therapy. <i>European Journal of Heart Failure</i> , 2016, 18, 457-468.	2.9	235
51	Time-to-Furosemide Treatment and Mortality in Patients Hospitalized With Acute Heart Failure. <i>Journal of the American College of Cardiology</i> , 2017, 69, 3042-3051.	1.2	235
52	Erythropoietin Induces Neovascularization and Improves Cardiac Function in Rats With Heart Failure After Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2005, 46, 125-133.	1.2	232
53	Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial. <i>Lancet</i> , The, 2016, 388, 2895-2903.	6.3	229
54	Advanced glycation end-products (AGEs) and heart failure: Pathophysiology and clinical implications. <i>European Journal of Heart Failure</i> , 2007, 9, 1146-1155.	2.9	224

#	ARTICLE	IF	CITATIONS
55	Erythropoietin improves cardiac function through endothelial progenitor cell and vascular endothelial growth factor mediated neovascularization. <i>European Heart Journal</i> , 2007, 28, 2018-2027.	1.0	210
56	The role of the kidney in heart failure. <i>European Heart Journal</i> , 2012, 33, 2135-2142.	1.0	209
57	Right ventricular dysfunction in heart failure with preserved ejection fraction: a systematic review and meta-analysis. <i>European Journal of Heart Failure</i> , 2016, 18, 1472-1487.	2.9	200
58	Identifying Pathophysiological Mechanisms in Heart Failure With Reduced Versus Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2018, 72, 1081-1090.	1.2	199
59	C-terminal proavopressin (copeptin) is a strong prognostic marker in patients with heart failure after an acute myocardial infarction: results from the OPTIMAAL study. <i>European Heart Journal</i> , 2009, 30, 1187-1194.	1.0	198
60	Diuretic response in acute heart failure—pathophysiology, evaluation, and therapy. <i>Nature Reviews Cardiology</i> , 2015, 12, 184-192.	6.1	198
61	Impaired left atrial function in heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2014, 16, 1096-1103.	2.9	194
62	How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). <i>European Journal of Heart Failure</i> , 2020, 22, 391-412.	2.9	193
63	Sex-specific cardiovascular structure and function in heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2014, 16, 535-542.	2.9	184
64	Development and validation of multivariable models to predict mortality and hospitalization in patients with heart failure. <i>European Journal of Heart Failure</i> , 2017, 19, 627-634.	2.9	183
65	Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document. <i>European Journal of Heart Failure</i> , 2013, 15, 1082-1094.	2.9	182
66	Urinary neutrophil gelatinase associated lipocalin (NGAL), a marker of tubular damage, is increased in patients with chronic heart failure. <i>European Journal of Heart Failure</i> , 2008, 10, 997-1000.	2.9	181
67	Tubular damage in chronic systolic heart failure is associated with reduced survival independent of glomerular filtration rate. <i>Heart</i> , 2010, 96, 1297-1302.	1.2	179
68	Prognostic value of plasma erythropoietin on mortality in patients with chronic heart failure. <i>Journal of the American College of Cardiology</i> , 2004, 44, 63-67.	1.2	178
69	Thirty Years of Evidence on the Efficacy of Drug Treatments for Chronic Heart Failure With Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2017, 10, .	1.6	178
70	A Single Bolus of a Long-acting Erythropoietin Analogue Darbepoetin Alfa in Patients with Acute Myocardial Infarction: A Randomized Feasibility and Safety Study. <i>Cardiovascular Drugs and Therapy</i> , 2006, 20, 135-141.	1.3	176
71	Clinical outcome of renal tubular damage in chronic heart failure. <i>European Heart Journal</i> , 2011, 32, 2705-2712.	1.0	174
72	Effects of Serelexin in Patients with Acute Heart Failure. <i>New England Journal of Medicine</i> , 2019, 381, 716-726.	13.9	174

#	ARTICLE	IF	CITATIONS
73	The clinical significance of interleukinâ€6 in heart failure: results from the BIOSTATâ€CHF study. <i>European Journal of Heart Failure</i> , 2019, 21, 965-973.	2.9	172
74	Effect of Vericiguat vs Placebo on Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 1512.	3.8	170
75	Protective Effects of Erythropoietin in Cardiac Ischemia. <i>Journal of the American College of Cardiology</i> , 2006, 48, 2161-2167.	1.2	167
76	Signature of circulating <sc>microRNAs</sc> in patients with acute heart failure. <i>European Journal of Heart Failure</i> , 2016, 18, 414-423.	2.9	162
77	The Predictive Value of Short-Term Changes in Hemoglobin Concentration in Patients Presenting With Acute Decompensated Heart Failure. <i>Journal of the American College of Cardiology</i> , 2013, 61, 1973-1981.	1.2	159
78	Identifying optimal doses of heart failure medications in men compared with women: a prospective, observational, cohort study. <i>Lancet, The</i> , 2019, 394, 1254-1263.	6.3	159
79	Both inâ€and outâ€hospital worsening of renal function predict outcome in patients with heart failure: results from the Coordinating Study Evaluating Outcome of Advising and Counseling in Heart Failure (COACH). <i>European Journal of Heart Failure</i> , 2009, 11, 847-854.	2.9	157
80	Prevalence, predictors and clinical outcome of residual congestion in acute decompensated heart failure. <i>International Journal of Cardiology</i> , 2018, 258, 185-191.	0.8	157
81	Effect of ivabradine in patients with heart failure with preserved ejection fraction: the <sc>EDIFY</sc> randomized placeboâ€controlled trial. <i>European Journal of Heart Failure</i> , 2017, 19, 1495-1503.	2.9	154
82	Renal effects of the angiotensin receptor neprilysin inhibitor <sc>LCZ696</sc> in patients with heart failure and preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2015, 17, 510-517.	2.9	153
83	Angiotensin II Type 1 Receptor A1166C Gene Polymorphism Is Associated With an Increased Response to Angiotensin II in Human Arteries. <i>Hypertension</i> , 2000, 35, 717-721.	1.3	149
84	A systems <sc>BIOlogy</sc> Study to <sc>TAilored</sc> Treatment in Chronic Heart Failure: rationale, design, and baseline characteristics of <sc>BIOSTATâ€CHF</sc>. <i>European Journal of Heart Failure</i> , 2016, 18, 716-726.	2.9	149
85	Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice. <i>European Heart Journal</i> , 2012, 33, 2782-2795.	1.0	148
86	Vitamin D status and outcomes in heart failure patients. <i>European Journal of Heart Failure</i> , 2011, 13, 619-625.	2.9	147
87	Definition of Iron Deficiency Based on the Gold Standard of Bone Marrow Iron Staining in Heart Failure Patients. <i>Circulation: Heart Failure</i> , 2018, 11, e004519.	1.6	147
88	A single dose of erythropoietin in ST-elevation myocardial infarction. <i>European Heart Journal</i> , 2010, 31, 2593-2600.	1.0	144
89	Adrenomedullin in heart failure: pathophysiology and therapeutic application. <i>European Journal of Heart Failure</i> , 2019, 21, 163-171.	2.9	144
90	Congestion in heart failure: a contemporary look at physiology, diagnosis and treatment. <i>Nature Reviews Cardiology</i> , 2020, 17, 641-655.	6.1	143

#	ARTICLE	IF	CITATIONS
91	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of the Oral Soluble Guanylate Cyclase Stimulator. <i>JACC: Heart Failure</i> , 2018, 6, 96-104.	1.9	141
92	Congestion in chronic systolic heart failure is related to renal dysfunction and increased mortality. <i>European Journal of Heart Failure</i> , 2010, 12, 974-982.	2.9	140
93	Non-cardiac comorbidities in heart failure with reduced, mid-range and preserved ejection fraction. <i>International Journal of Cardiology</i> , 2018, 271, 132-139.	0.8	140
94	Correlation with invasive left ventricular filling pressures and prognostic relevance of the echocardiographic diastolic parameters used in the 2016 ESC heart failure guidelines and in the 2016 ASE/EACVI recommendations: a systematic review in patients with heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2018, 20, 1303-1311.	2.9	138
95	Erythropoietin in cardiovascular diseases. <i>European Heart Journal</i> , 2004, 25, 285-291.	1.0	136
96	Effects of quinapril on clinical outcome after coronary artery bypass grafting (the QUO VADIS study). <i>American Journal of Cardiology</i> , 2001, 87, 542-546.	0.7	135
97	Anaemia in chronic heart failure is not only related to impaired renal perfusion and blunted erythropoietin production, but to fluid retention as well. <i>European Heart Journal</i> , 2006, 28, 166-171.	1.0	134
98	Diuretic response in patients with acute decompensated heart failure: characteristics and clinical outcome – an analysis from RELAX-AHF. <i>European Journal of Heart Failure</i> , 2014, 16, 1230-1240.	2.9	134
99	Improving risk prediction in heart failure using machine learning. <i>European Journal of Heart Failure</i> , 2020, 22, 139-147.	2.9	132
100	Refining success of cardiac resynchronization therapy using a simple score predicting the amount of reverse ventricular remodelling: results from the Markers and Response to CRT (MARC) study. <i>Europace</i> , 2018, 20, e1-e10.	0.7	131
101	Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2017, 5, 92-98.	1.9	129
102	Effects of the Adenosine A1 Receptor Antagonist Rolofylline on Renal Function in Patients With Acute Heart Failure and Renal Dysfunction. <i>Journal of the American College of Cardiology</i> , 2011, 57, 1899-1907.	1.2	125
103	Design of a Phase 2b Trial of Intracoronary Administration of AAV1/SERCA2a in Patients With Advanced Heart Failure. <i>JACC: Heart Failure</i> , 2014, 2, 84-92.	1.9	123
104	Volume Status and Diuretic Therapy in Systolic Heart Failure and the Detection of Early Abnormalities in Renal and Tubular Function. <i>Journal of the American College of Cardiology</i> , 2011, 57, 2233-2241.	1.2	121
105	Levels of Hematopoiesis Inhibitor N-Acetyl-Seryl-Aspartyl-Lysyl-Proline Partially Explain the Occurrence of Anemia in Heart Failure. <i>Circulation</i> , 2005, 112, 1743-1747.	1.6	120
106	Clinical and prognostic effects of atrial fibrillation in heart failure patients with reduced and preserved left ventricular ejection fraction. <i>European Journal of Heart Failure</i> , 2011, 13, 1111-1120.	2.9	119
107	Risk of complications during pregnancy after Senning or Mustard (atrial) repair of complete transposition of the great arteries. <i>European Heart Journal</i> , 2005, 26, 2588-2595.	1.0	118
108	Soluble guanylate cyclase: a potential therapeutic target for heart failure. <i>Heart Failure Reviews</i> , 2013, 18, 123-134.	1.7	118

#	ARTICLE	IF	CITATIONS
109	Patient Selection in Heart Failure With Preserved Ejection Fraction Clinical Trials. <i>Journal of the American College of Cardiology</i> , 2015, 65, 1668-1682.	1.2	116
110	The PROTECT in-hospital risk model: 7-day outcome in patients hospitalized with acute heart failure and renal dysfunction. <i>European Journal of Heart Failure</i> , 2012, 14, 605-612.	2.9	115
111	A Systematic Review and Network Meta-Analysis of Pharmacological Treatment of Heart Failure With Reduced Ejection Fraction. <i>JACC: Heart Failure</i> , 2022, 10, 73-84.	1.9	115
112	Relaxin, a pleiotropic vasodilator for the treatment of heart failure. <i>Heart Failure Reviews</i> , 2009, 14, 321-329.	1.7	113
113	Decongestion in acute heart failure. <i>European Journal of Heart Failure</i> , 2014, 16, 471-482.	2.9	113
114	Prescribing patterns of evidence-based heart failure pharmacotherapy and outcomes in the ASIAN-HF registry: a cohort study. <i>The Lancet Global Health</i> , 2018, 6, e1008-e1018.	2.9	113
115	Serial high sensitivity cardiac troponin T measurement in acute heart failure: insights from the <scp>RELAX-AHF</scp> study. <i>European Journal of Heart Failure</i> , 2015, 17, 1262-1270.	2.9	110
116	Diuretic response in acute heart failure—an analysis from ASCEND-HF. <i>American Heart Journal</i> , 2015, 170, 313-321.e4.	1.2	110
117	The effects of liraglutide and dapagliflozin on cardiac function and structure in a multi-hit mouse model of heart failure with preserved ejection fraction. <i>Cardiovascular Research</i> , 2021, 117, 2108-2124.	1.8	108
118	Predictors of Postdischarge Outcomes From Information Acquired Shortly After Admission for Acute Heart Failure. <i>Circulation: Heart Failure</i> , 2014, 7, 76-87.	1.6	107
119	Smoking and Cardiac Events After Venous Coronary Bypass Surgery. <i>Circulation</i> , 1996, 93, 42-47.	1.6	107
120	Obstetric complications in Marfan syndrome. <i>International Journal of Cardiology</i> , 2006, 110, 53-59.	0.8	106
121	A randomized, double-blind, placebo-controlled, multicentre study to assess haemodynamic effects of serelaxin in patients with acute heart failure. <i>European Heart Journal</i> , 2014, 35, 431-441.	1.0	104
122	Serelaxin in addition to standard therapy in acute heart failure: rationale and design of the RELAX-AHF-2 study. <i>European Journal of Heart Failure</i> , 2017, 19, 800-809.	2.9	104
123	N-terminal pro-B-type natriuretic peptide is an independent predictor of cardiovascular morbidity and mortality in the general population. <i>European Heart Journal</i> , 2010, 31, 120-127.	1.0	103
124	The Chronic Kidney Disease Epidemiology Collaboration equation outperforms the Modification of Diet in Renal Disease equation for estimating glomerular filtration rate in chronic systolic heart failure. <i>European Journal of Heart Failure</i> , 2014, 16, 86-94.	2.9	102
125	Biased ligand of the angiotensin II type 1 receptor in patients with acute heart failure: a randomized, double-blind, placebo-controlled, phase IIB, dose ranging trial (BLAST-AHF). <i>European Heart Journal</i> , 2017, 38, 2364-2373.	1.0	102
126	Differential associations between renal function and modifiable risk factors in patients with chronic heart failure. <i>Clinical Research in Cardiology</i> , 2009, 98, 121-129.	1.5	101



#	ARTICLE	IF	CITATIONS
127	Effects of alagebrium, an advanced glycation endproduct breaker, on exercise tolerance and cardiac function in patients with chronic heart failure. <i>European Journal of Heart Failure</i> , 2011, 13, 899-908.	2.9	101
128	Troponin I in acute decompensated heart failure: insights from the ASCEND-HF study. <i>European Journal of Heart Failure</i> , 2012, 14, 1257-1264.	2.9	101
129	Early drop in systolic blood pressure and worsening renal function in acute heart failure: renal results of Pre-RELAX-AHF. <i>European Journal of Heart Failure</i> , 2011, 13, 961-967.	2.9	99
130	Plasma Biomarkers Reflecting Profibrotic Processes in Heart Failure With a Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2016, 9, .	1.6	93
131	Right ventricular-vascular coupling in heart failure with preserved ejection fraction and pre- vs. post-capillary pulmonary hypertension. <i>European Heart Journal Cardiovascular Imaging</i> , 2018, 19, 425-432.	0.5	93
132	Prognostic Value of Plasma Neutrophil Gelatinase-Associated Lipocalin for Mortality in Patients With Heart Failure. <i>Circulation: Heart Failure</i> , 2014, 7, 35-42.	1.6	92
133	Influence of age on natriuretic peptides in patients with chronic heart failure: a comparison between ANP/NT-ANP and BNP/NT-proBNP. <i>European Journal of Heart Failure</i> , 2005, 7, 81-86.	2.9	90
134	Serelaxin in acute heart failure patients with preserved left ventricular ejection fraction: results from the RELAX-AHF trial. <i>European Heart Journal</i> , 2014, 35, 1041-1050.	1.0	90
135	Renin-Angiotensin System Inhibition, Worsening Renal Function, and Outcome in Heart Failure Patients With Reduced and Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2017, 10, .	1.6	89
136	Echocardiographic estimation of left ventricular and pulmonary pressures in patients with heart failure and preserved ejection fraction: a study utilizing simultaneous echocardiography and invasive measurements. <i>European Journal of Heart Failure</i> , 2017, 19, 1651-1660.	2.9	89
137	Dyspnoea and worsening heart failure in patients with acute heart failure: results from the Pre-RELAX-AHF study. <i>European Journal of Heart Failure</i> , 2010, 12, 1130-1139.	2.9	88
138	Extracorporeal Ultrafiltration for Fluid Overload in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2017, 69, 2428-2445.	1.2	88
139	N-Terminal Pro-B-Type Natriuretic Peptide and Clinical Outcomes. <i>JACC: Heart Failure</i> , 2020, 8, 931-939.	1.9	88
140	Hemodialysis-Induced Regional Left Ventricular Systolic Dysfunction. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2012, 7, 1615-1623.	2.2	87
141	Tubular Damage and Worsening Renal Function in Chronic Heart Failure. <i>JACC: Heart Failure</i> , 2013, 1, 417-424.	1.9	87
142	Bone marrow dysfunction in chronic heart failure patients. <i>European Journal of Heart Failure</i> , 2010, 12, 676-684.	2.9	86
143	Incremental Prognostic Power of Novel Biomarkers (Growth-Differentiation Factor-15, Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 10) Advanced Chronic Heart Failure. <i>American Journal of Cardiology</i> , 2013, 112, 831-837.	0.7	86
144	Growth differentiation factor 15 (GDF-15) in patients admitted for acute heart failure: results from the RELAX-AHF study. <i>European Journal of Heart Failure</i> , 2015, 17, 1133-1143.	2.9	86

#	ARTICLE	IF	CITATIONS
145	Prevalence, incidence, and prognostic value of anaemia in patients after an acute myocardial infarction: data from the OPTIMAAL trial. <i>European Heart Journal</i> , 2009, 30, 1331-1339.	1.0	85
146	Waist-to-hip ratio and mortality in heart failure. <i>European Journal of Heart Failure</i> , 2018, 20, 1269-1277.	2.9	85
147	Early dyspnoea relief in acute heart failure: prevalence, association with mortality, and effect of rolofylline in the PROTECT Study. <i>European Heart Journal</i> , 2011, 32, 1519-1534.	1.0	84
148	Body Weight Change During and After Hospitalization for Acute Heart Failure: Patient Characteristics, Markers of Congestion, and Outcomes. <i>JACC: Heart Failure</i> , 2017, 5, 1-13.	1.9	84
149	Selenium and outcome in heart failure. <i>European Journal of Heart Failure</i> , 2020, 22, 1415-1423.	2.9	84
150	The Cardiorenal Syndrome in Heart Failure. <i>Progress in Cardiovascular Diseases</i> , 2011, 54, 144-153.	1.6	83
151	Neurohormonal and clinical sex differences in heart failure. <i>European Heart Journal</i> , 2013, 34, 2538-2547.	1.0	83
152	Anaemia and renal dysfunction are independently associated with BNP and NT-proBNP levels in patients with heart failure. <i>European Journal of Heart Failure</i> , 2007, 9, 787-794.	2.9	82
153	Impact of Serial Troponin Release on Outcomes in Patients With Acute Heart Failure. <i>Circulation: Heart Failure</i> , 2011, 4, 724-732.	1.6	82
154	A multimarker multi-time point based risk stratification strategy in acute heart failure: results from the RELAX-AHF trial. <i>European Journal of Heart Failure</i> , 2017, 19, 1001-1010.	2.9	81
155	Pregnancy in women with corrected tetralogy of Fallot: Occurrence and predictors of adverse events. <i>American Heart Journal</i> , 2011, 161, 307-313.	1.2	80
156	Elevation in High-Sensitivity Troponin T in Heart Failure and Preserved Ejection Fraction and Influence of Treatment With the Angiotensin Receptor Neprilysin Inhibitor LCZ696. <i>Circulation: Heart Failure</i> , 2014, 7, 953-959.	1.6	80
157	Hypochloremia, Diuretic Resistance, and Outcome in Patients With Acute Heart Failure. <i>Circulation: Heart Failure</i> , 2016, 9, .	1.6	80
158	Renal tubular resistance is the primary driver for loop diuretic resistance in acute heart failure. <i>European Journal of Heart Failure</i> , 2017, 19, 1014-1022.	2.9	80
159	Effects of empagliflozin on renal sodium and glucose handling in patients with acute heart failure. <i>European Journal of Heart Failure</i> , 2021, 23, 68-78.	2.9	79
160	Mineralocorticoid receptor antagonist pattern of use in heart failure with reduced ejection fraction: findings from BIOSTAT-CHF. <i>European Journal of Heart Failure</i> , 2017, 19, 1284-1293.	2.9	79
161	Effects of Nesiritide and Predictors of Urine Output in Acute Decompensated Heart Failure. <i>Journal of the American College of Cardiology</i> , 2013, 62, 1177-1183.	1.2	78
162	Association between renal function and cardiovascular structure and function in heart failure with preserved ejection fraction. <i>European Heart Journal</i> , 2014, 35, 3442-3451.	1.0	78

#	ARTICLE	IF	CITATIONS
163	Biomarker Profiles of Acute Heart Failure Patients With a Mid-Range Ejection Fraction. <i>JACC: Heart Failure</i> , 2017, 5, 507-517.	1.9	78
164	Low Recurrence of Angina Pectoris After Coronary Artery Bypass Graft Surgery With Bilateral Internal Thoracic and Right Gastroepiploic Arteries. <i>Circulation</i> , 1998, 97, 2402-2405.	1.6	76
165	Clinical and prognostic value of advanced glycation end-products in chronic heart failure. <i>European Heart Journal</i> , 2007, 28, 2879-2885.	1.0	76
166	Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study in Heart Failure (ARTS in HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease. <i>European Journal of Heart Failure</i> , 2015, 17, 224-232.	2.9	74
167	Traditional and new composite endpoints in heart failure clinical trials: facilitating comprehensive efficacy assessments and improving trial efficiency. <i>European Journal of Heart Failure</i> , 2016, 18, 482-489.	2.9	74
168	Blood urea nitrogen-to-creatinine ratio in the general population and in patients with acute heart failure. <i>Heart</i> , 2017, 103, 407-413.	1.2	74
169	Adequacy of endogenous erythropoietin levels and mortality in anaemic heart failure patients. <i>European Heart Journal</i> , 2008, 29, 1510-1515.	1.0	72
170	Low-dose erythropoietin improves cardiac function in experimental heart failure without increasing haematocrit. <i>European Journal of Heart Failure</i> , 2008, 10, 22-29.	2.9	72
171	Vascular endothelial growth factor is crucial for erythropoietin-induced improvement of cardiac function in heart failure. <i>Cardiovascular Research</i> , 2010, 87, 30-39.	1.8	72
172	Low pulse pressure is independently related to elevated natriuretic peptides and increased mortality in advanced chronic heart failure. <i>European Heart Journal</i> , 2005, 26, 1759-1764.	1.0	71
173	The vitamin D receptor activator paricalcitol prevents fibrosis and diastolic dysfunction in a murine model of pressure overload. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2012, 132, 282-289.	1.2	71
174	International differences in clinical characteristics, management, and outcomes in acute heart failure patients: better short-term outcomes in patients enrolled in Eastern Europe and Russia in the PROTECT trial. <i>European Journal of Heart Failure</i> , 2014, 16, 614-624.	2.9	71
175	Hemoglobin levels and 30-day mortality in patients after myocardial infarction. <i>International Journal of Cardiology</i> , 2005, 100, 289-292.	0.8	70
176	Abnormal liver function tests in acute heart failure: relationship with clinical characteristics and outcome in the PROTECT study. <i>European Journal of Heart Failure</i> , 2016, 18, 830-839.	2.9	70
177	Machine learning based on biomarker profiles identifies distinct subgroups of heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2021, 23, 983-991.	2.9	70
178	Cardiac complications relating to pregnancy and recurrence of disease in the offspring of women with atrioventricular septal defects. <i>European Heart Journal</i> , 2005, 26, 2581-2587.	1.0	69
179	Optimizing clinical use of biomarkers in high-risk acute heart failure patients. <i>European Journal of Heart Failure</i> , 2016, 18, 269-280.	2.9	69
180	Hospitalization for Recently Diagnosed Versus Worsening Chronic Heart Failure. <i>Journal of the American College of Cardiology</i> , 2017, 69, 3029-3039.	1.2	69

#	ARTICLE	IF	CITATIONS
181	Iron deficiency in worsening heart failure is associated with reduced estimated protein intake, fluid retention, inflammation, and antiplatelet use. <i>European Heart Journal</i> , 2019, 40, 3616-3625.	1.0	69
182	Heart Failure Therapeutics on the Basis of Biased Ligand of the Angiotensin-2 Type 1 Receptor. <i>JACC: Heart Failure</i> , 2015, 3, 193-201.	1.9	68
183	Plasma levels of heart failure biomarkers are primarily a reflection of extracardiac production. <i>Theranostics</i> , 2018, 8, 4155-4169.	4.6	68
184	Association with outcomes and response to treatment of trimethylamine N-oxide in heart failure: results from BIOSTAT-CHF. <i>European Journal of Heart Failure</i> , 2019, 21, 877-886.	2.9	68
185	Tissue advanced glycation end products are associated with diastolic function and aerobic exercise capacity in diabetic heart failure patients. <i>European Journal of Heart Failure</i> , 2011, 13, 76-82.	2.9	67
186	Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, LCZ696, in patients with heart failure with preserved ejection fraction: an analysis of the PARAMOUNT trial. <i>European Journal of Heart Failure</i> , 2014, 16, 671-677.	2.9	67
187	What have we learned about heart failure with mid-range ejection fraction one year after its introduction?. <i>European Journal of Heart Failure</i> , 2017, 19, 1569-1573.	2.9	67
188	Sodium-glucose cotransporter 2 inhibitors as an early, first-line therapy in patients with heart failure and reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2022, 24, 431-441.	2.9	67
189	Low circulating microRNA levels in heart failure patients are associated with atherosclerotic disease and cardiovascular-related rehospitalizations. <i>Clinical Research in Cardiology</i> , 2017, 106, 598-609.	1.5	66
190	Right Heart Dysfunction in Heart Failure With Preserved Ejection Fraction: The Impact of Atrial Fibrillation. <i>Journal of Cardiac Failure</i> , 2018, 24, 177-185.	0.7	65
191	Baseline features of the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with) Tj ETQq1 1 0.784314 rgBT / Overlock 10 Tf 50 65	2.9	65
192	Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2020, 41, 2109-2117.	1.0	65
193	Effects of Empagliflozin on Symptoms, Physical Limitations, and Quality of Life in Patients Hospitalized for Acute Heart Failure: Results From the EMPULSE Trial. <i>Circulation</i> , 2022, 146, 279-288.	1.6	65
194	Association of obesity with heart failure outcomes in 11 Asian regions: A cohort study. <i>PLoS Medicine</i> , 2019, 16, e1002916.	3.9	64
195	Bioadrenomedullin as a marker of congestion in patients with new-onset and worsening heart failure. <i>European Journal of Heart Failure</i> , 2019, 21, 732-743.	2.9	64
196	Dual pathway for angiotensin II formation in human internal mammary arteries. <i>British Journal of Pharmacology</i> , 1998, 125, 1028-1032.	2.7	62
197	Left ventricular dyssynchrony in patients with heart failure and preserved ejection fraction. <i>European Heart Journal</i> , 2014, 35, 42-47.	1.0	61
198	Effect of Spironolactone on 30-Day Death and Heart Failure Rehospitalization (from the COACH) Tj ETQq0 0 0 rgBT / Overlock 10 Tf 50 61	0.7	61

#	ARTICLE	IF	CITATIONS
199	Fibrosis Marker Syndecan-1 and Outcome in Patients With Heart Failure With Reduced and Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2014, 7, 457-462.	1.6	60
200	Renal Function Trajectories and Clinical Outcomes in Acute Heart Failure. <i>Circulation: Heart Failure</i> , 2014, 7, 59-67.	1.6	60
201	Sex-specific associations of obesity and N-terminal pro-B-type natriuretic peptide levels in the general population. <i>European Journal of Heart Failure</i> , 2018, 20, 1205-1214.	2.9	60
202	Sodium-glucose cotransporter 2 inhibition in patients hospitalized for acute decompensated heart failure: rationale for and design of the EMPULSE trial. <i>European Journal of Heart Failure</i> , 2021, 23, 826-834.	2.9	60
203	Dyspnoea in patients with acute heart failure: an analysis of its clinical course, determinants, and relationship to 60-day outcomes in the PROTECT pilot study. <i>European Journal of Heart Failure</i> , 2010, 12, 499-507.	2.9	59
204	The additive burden of iron deficiency in the cardiorenal-anaemia axis: scope of a problem and its consequences. <i>European Journal of Heart Failure</i> , 2014, 16, 655-662.	2.9	59
205	The cardiopulmonary continuum systemic inflammation as "common soil" of heart and lung disease. <i>International Journal of Cardiology</i> , 2010, 145, 172-176.	0.8	58
206	Prognostic Significance of Creatinine Increases During an Acute Heart Failure Admission in Patients With and Without Residual Congestion. <i>Circulation: Heart Failure</i> , 2018, 11, e004644.	1.6	58
207	CA125-Guided Diuretic Treatment Versus Usual Care in Patients With Acute Heart Failure and Renal Dysfunction. <i>American Journal of Medicine</i> , 2020, 133, 370-380.e4.	0.6	58
208	Renal function and the effects of vericiguat in patients with worsening heart failure with reduced ejection fraction: insights from the VICTORIA (Vericiguat Global Study in) Tj ETQq0 0 0 rgBj/Overlook 10 Tf 50	2.9	58
209	High-Sensitivity C-Reactive Protein in Acute Heart Failure: Insights From the ASCEND-HF Trial. <i>Journal of Cardiac Failure</i> , 2014, 20, 319-326.	0.7	57
210	Potassium and the use of renin-angiotensin-aldosterone system inhibitors in heart failure with reduced ejection fraction: data from BIOSAT-CHEF. <i>European Journal of Heart Failure</i> , 2018, 20, 923-930.	2.9	57
211	Clinical Role of CA125 in Worsening Heart Failure. <i>JACC: Heart Failure</i> , 2020, 8, 386-397.	1.9	57
212	Evidence-Based Medical Therapy in Patients With Heart Failure With Reduced Ejection Fraction and Chronic Kidney Disease. <i>Circulation</i> , 2022, 145, 693-712.	1.6	57
213	Endogenous Erythropoietin and Outcome in Heart Failure. <i>Circulation</i> , 2010, 121, 245-251.	1.6	56
214	Effects of serelaxin in subgroups of patients with acute heart failure: results from RELAX-AHF. <i>European Heart Journal</i> , 2013, 34, 3128-3136.	1.0	56
215	Effect of Serelaxin on Mode of Death in Acute Heart Failure. <i>Journal of the American College of Cardiology</i> , 2014, 64, 1591-1598.	1.2	56
216	Exclusive use of arterial grafts in coronary artery bypass operations for three-vessel disease: Use of both thoracic arteries and the gastroepiploic artery in 256 consecutive patients. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 1996, 112, 935-942.	0.4	55

#	ARTICLE	IF	CITATIONS
217	The VEGF +405 CC Promoter Polymorphism is Associated With an Impaired Prognosis in Patients With Chronic Heart Failure: A MERIT-HF Substudy. <i>Journal of Cardiac Failure</i> , 2005, 11, 279-284.	0.7	55
218	Biomarkers and low risk in heart failure. Data from <scp>COACH</scp> and <scp>TRIUMPH</scp>. <i>European Journal of Heart Failure</i> , 2015, 17, 1271-1282.	2.9	55
219	Partial adenosine A1 receptor agonism: a potential new therapeutic strategy for heart failure. <i>Heart Failure Reviews</i> , 2016, 21, 95-102.	1.7	55
220	Fibroblast growth factor 23 is related to profiles indicating volume overload, poor therapy optimization and prognosis in patients with new-onset and worsening heart failure. <i>International Journal of Cardiology</i> , 2018, 253, 84-90.	0.8	55
221	Clinical importance of urinary sodium excretion in acute heart failure. <i>European Journal of Heart Failure</i> , 2020, 22, 1438-1447.	2.9	55
222	Iron deficiency and red cell indices in patients with heart failure. <i>European Journal of Heart Failure</i> , 2018, 20, 114-122.	2.9	54
223	Use of biomarkers to establish potential role and function of circulating microRNAs in acute heart failure. <i>International Journal of Cardiology</i> , 2016, 224, 231-239.	0.8	53
224	A network analysis to compare biomarker profiles in patients with and without diabetes mellitus in acute heart failure. <i>European Journal of Heart Failure</i> , 2017, 19, 1310-1320.	2.9	53
225	Effects of erythropoietin after an acute myocardial infarction: Rationale and study design of a prospective, randomized, clinical trial (HEBE III). <i>American Heart Journal</i> , 2008, 155, 817-822.	1.2	52
226	Vasodilators in the treatment of acute heart failure: what we know, what we don't. <i>Heart Failure Reviews</i> , 2009, 14, 299-307.	1.7	52
227	Erythropoietin Stimulates Normal Endothelial Progenitor Cell-Mediated Endothelial Turnover, but Attributes to Neovascularization Only in the Presence of Local Ischemia. <i>Cardiovascular Drugs and Therapy</i> , 2008, 22, 265-274.	1.3	51
228	Efficacy and Safety of Spironolactone in Patients With HFpEF and Chronic Kidney Disease. <i>JACC: Heart Failure</i> , 2019, 7, 25-32.	1.9	51
229	Interleukin 6 and Development of Heart Failure With Preserved Ejection Fraction in the General Population. <i>Journal of the American Heart Association</i> , 2021, 10, e018549.	1.6	51
230	Telomere length and psychological well-being in patients with chronic heart failure. <i>Age and Ageing</i> , 2010, 39, 223-227.	0.7	50
231	Finerenone: third-generation mineralocorticoid receptor antagonist for the treatment of heart failure and diabetic kidney disease. <i>Expert Opinion on Investigational Drugs</i> , 2015, 24, 1123-1135.	1.9	50
232	Effects of sildenafil on cardiac structure and function, cardiopulmonary exercise testing and health-related quality of life measures in heart failure patients with preserved ejection fraction and pulmonary hypertension. <i>European Journal of Heart Failure</i> , 2017, 19, 116-125.	2.9	50
233	Concentric vs. eccentric remodelling in heart failure with reduced ejection fraction: clinical characteristics, pathophysiology and response to treatment. <i>European Journal of Heart Failure</i> , 2020, 22, 1147-1155.	2.9	50
234	The (pro)renin receptor in health and disease. <i>Annals of Medicine</i> , 2010, 42, 13-18.	1.5	49

#	ARTICLE	IF	CITATIONS
235	Sex-specific acute heart failure phenotypes and outcomes from PROTECT. <i>European Journal of Heart Failure</i> , 2013, 15, 1374-1381.	2.9	49
236	Use of High-Sensitivity Troponin T to Identify Patients With Acute Heart Failure at Lower Risk for Adverse Outcomes. <i>JACC: Heart Failure</i> , 2016, 4, 591-599.	1.9	49
237	Patient journey after admission for acute heart failure: length of stay, 30-day readmission and 90-day mortality. <i>European Journal of Heart Failure</i> , 2016, 18, 1041-1050.	2.9	49
238	Effects of danicamtiv, a novel cardiac myosin activator, in heart failure with reduced ejection fraction: experimental data and clinical results from a phase 2a trial. <i>European Journal of Heart Failure</i> , 2020, 22, 1649-1658.	2.9	49
239	High Prevalence of Microalbuminuria in Chronic Heart Failure Patients. <i>Journal of Cardiac Failure</i> , 2005, 11, 602-606.	0.7	48
240	Co-morbidities in heart failure. <i>Heart Failure Reviews</i> , 2014, 19, 163-172.	1.7	48
241	Acute heart failure in elderly patients: worse outcomes and differential utility of standard prognostic variables. Insights from the PROTECT trial. <i>European Journal of Heart Failure</i> , 2015, 17, 109-118.	2.9	48
242	Serially measured circulating microRNAs and adverse clinical outcomes in patients with acute heart failure. <i>European Journal of Heart Failure</i> , 2018, 20, 89-96.	2.9	48
243	Mild preoperative renal dysfunction as a predictor of long-term clinical outcome after coronary bypass surgery. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2005, 129, 330-335.	0.4	47
244	Increased mortality with elevated plasma endothelin-1 in acute heart failure: an ASCEND-HF biomarker substudy. <i>European Journal of Heart Failure</i> , 2016, 18, 290-297.	2.9	47
245	Torsemide Versus Furosemide in Patients With Acute Heart Failure (from the ASCEND-HF Trial). <i>American Journal of Cardiology</i> , 2016, 117, 404-411.	0.7	47
246	Comparing biomarker profiles of patients with heart failure: atrial fibrillation vs. sinus rhythm and reduced vs. preserved ejection fraction. <i>European Heart Journal</i> , 2018, 39, 3867-3875.	1.0	47
247	Effect of Neladenoson Bialanate on Exercise Capacity Among Patients With Heart Failure With Preserved Ejection Fraction. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 2101.	3.8	47
248	Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC-HF baseline characteristics and comparison with contemporary clinical trials. <i>European Journal of Heart Failure</i> , 2020, 22, 2160-2171.	2.9	47
249	The association of long-term outcome and biological sex in patients with acute heart failure from different geographic regions. <i>European Heart Journal</i> , 2020, 41, 1357-1364.	1.0	47
250	Effects of oral appliances and CPAP on the left ventricle and natriuretic peptides. <i>International Journal of Cardiology</i> , 2008, 128, 232-239.	0.8	46
251	High soluble transferrin receptor in patients with heart failure: a measure of iron deficiency and a strong predictor of mortality. <i>European Journal of Heart Failure</i> , 2021, 23, 919-932.	2.9	46
252	Effects of Elamipretide on Left Ventricular Function in Patients With Heart Failure With Reduced Ejection Fraction: The PROGRESS-HF Phase 2 Trial. <i>Journal of Cardiac Failure</i> , 2020, 26, 429-437.	0.7	46

#	ARTICLE	IF	CITATIONS
253	Prognostic Value of Baseline and Changes in Circulating Soluble ST2 Levels and the Effects of Nesiritide in Acute Decompensated Heart Failure. <i>JACC: Heart Failure</i> , 2016, 4, 68-77.	1.9	45
254	Comorbidities in Heart Failure. <i>Handbook of Experimental Pharmacology</i> , 2017, 243, 35-66.	0.9	45
255	Epicardial Adipose Tissue and Invasive Hemodynamics in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2020, 8, 667-676.	1.9	45
256	Statins in the Treatment of Chronic Heart Failure: A Systematic Review. <i>PLoS Medicine</i> , 2006, 3, e333.	3.9	44
257	Statins in the treatment of chronic heart failure: Biological and clinical considerations. <i>Cardiovascular Research</i> , 2006, 71, 443-454.	1.8	44
258	Possible Association Between Telomere Length and Renal Dysfunction in Patients With Chronic Heart Failure. <i>American Journal of Cardiology</i> , 2008, 102, 207-210.	0.7	44
259	Clinical use of novel biomarkers in heart failure: towards personalized medicine. <i>Heart Failure Reviews</i> , 2014, 19, 369-381.	1.7	44
260	Worsening Heart Failure Following Admission for Acute Heart Failure. <i>JACC: Heart Failure</i> , 2015, 3, 395-403.	1.9	44
261	Heart failure in the outpatient versus inpatient setting: findings from the BIOSTAT-CHF study. <i>European Journal of Heart Failure</i> , 2019, 21, 112-120.	2.9	44
262	Renal Compression in Heart Failure. <i>JACC: Heart Failure</i> , 2022, 10, 175-183.	1.9	44
263	Skin-Autofluorescence, a Measure of Tissue Advanced Glycation End-Products (AGEs), is Related to Diastolic Function in Dialysis Patients. <i>Journal of Cardiac Failure</i> , 2008, 14, 596-602.	0.7	43
264	Hemoconcentration-guided Diuresis in Heart Failure. <i>American Journal of Medicine</i> , 2014, 127, 1154-1159.	0.6	43
265	The PCSK9-LDL Receptor Axis and Outcomes in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2017, 70, 2128-2136.	1.2	43
266	Differences in Clinical Profile and Outcomes of Low Iron Storage vs Defective Iron Utilization in Patients With Heart Failure. <i>JAMA Cardiology</i> , 2019, 4, 696.	3.0	43
267	Prognostic importance of renal function in patients with early heart failure and mild left ventricular dysfunction. <i>American Journal of Cardiology</i> , 2004, 94, 240-243.	0.7	42
268	Effects of alagebrium, an advanced glycation end-product breaker, in patients with chronic heart failure: study design and baseline characteristics of the BENEFICIAL trial. <i>European Journal of Heart Failure</i> , 2010, 12, 294-300.	2.9	42
269	Prognostic value of N-terminal pro-B-type natriuretic peptide in heart failure patients with preserved and reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2014, 16, 958-966.	2.9	42
270	The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT. <i>European Journal of Heart Failure</i> , 2014, 16, 426-434.	2.9	42



#	ARTICLE	IF	CITATIONS
271	Clinical correlates and prognostic impact of impaired iron storage versus impaired iron transport in an international cohort of 1821 patients with chronic heart failure. <i>International Journal of Cardiology</i> , 2017, 243, 360-366.	0.8	42
272	Atrial fibrillation modifies the association between pulmonary artery wedge pressure and left ventricular end-diastolic pressure. <i>European Journal of Heart Failure</i> , 2017, 19, 1483-1490.	2.9	42
273	Aetiology, timing and clinical predictors of early vs. late readmission following index hospitalization for acute heart failure: insights from ASCEND-HF. <i>European Journal of Heart Failure</i> , 2018, 20, 304-314.	2.9	42
274	Nesiritide, Renal Function, and Associated Outcomes During Hospitalization for Acute Decompensated Heart Failure. <i>Circulation</i> , 2014, 130, 958-965.	1.6	41
275	The Safety of an Adenosine A1-Receptor Antagonist, Rolofylline, in Patients with Acute Heart Failure and Renal Impairment. <i>Drug Safety</i> , 2012, 35, 233-244.	1.4	40
276	The WAP Four-Disulfide Core Domain Protein HE4: A Novel Biomarker for Heart Failure. <i>JACC: Heart Failure</i> , 2013, 1, 164-169.	1.9	40
277	IGFBP7 (Insulin-Like Growth Factor-Binding Protein-7) and Neprilysin Inhibition in Patients With Heart Failure. <i>Circulation: Heart Failure</i> , 2018, 11, e005133.	1.6	40
278	Advancing Research on the Complex Interrelations Between Atrial Fibrillation and Heart Failure. <i>Circulation</i> , 2020, 141, 1915-1926.	1.6	40
279	Sex-Specific Differences in Heart Failure: Pathophysiology, Risk Factors, Management, and Outcomes. <i>Canadian Journal of Cardiology</i> , 2021, 37, 560-571.	0.8	40
280	Effect of Intensive Versus Moderate Lipid Lowering on Endothelial Function and Vascular Responsiveness to Angiotensin II in Stable Coronary Artery Disease. <i>American Journal of Cardiology</i> , 2005, 96, 1361-1364.	0.7	39
281	Overview of emerging pharmacologic agents for acute heart failure syndromes. <i>European Journal of Heart Failure</i> , 2008, 10, 201-213.	2.9	39
282	Urinary N-Terminal Prohormone Brain Natriuretic Peptide Excretion in Patients With Chronic Heart Failure. <i>Circulation</i> , 2009, 120, 35-41.	1.6	39
283	Serum Potassium Levels and Outcome in Acute Heart Failure (Data from the PROTECT and COACH) $T_j \text{ ETQq1 } 1 \text{ } 0.784314 \text{ } \text{rgBT} / \text{Overl}$	0.7	39
284	Advanced Glycation Endproducts in Chronic Heart Failure. <i>Annals of the New York Academy of Sciences</i> , 2008, 1126, 225-230.	1.8	38
285	Advanced glycation end-products, a pathophysiological pathway in the cardiorenal syndrome. <i>Heart Failure Reviews</i> , 2012, 17, 221-228.	1.7	38
286	Current and novel renal biomarkers in heart failure. <i>Heart Failure Reviews</i> , 2012, 17, 241-250.	1.7	38
287	Liver Function, In-Hospital, and Post-Discharge Clinical Outcome in Patients With Acute Heart Failure—Results From the Relaxin for the Treatment of Patients With Acute Heart Failure Study. <i>Journal of Cardiac Failure</i> , 2014, 20, 407-413.	0.7	38
288	Erythropoietin in the General Population: Reference Ranges and Clinical, Biochemical and Genetic Correlates. <i>PLoS ONE</i> , 2015, 10, e0125215.	1.1	38

#	ARTICLE	IF	CITATIONS
289	2016 ESC and ACC/AHA/HFSA heart failure guideline update – what is new and why is it important?. <i>Nature Reviews Cardiology</i> , 2016, 13, 623-628.	6.1	38
290	Serum ferritin and risk for new-onset heart failure and cardiovascular events in the community. <i>European Journal of Heart Failure</i> , 2017, 19, 348-356.	2.9	38
291	OPLAH ablation leads to accumulation of 5-oxoproline, oxidative stress, fibrosis, and elevated fillings pressures: a murine model for heart failure with a preserved ejection fraction. <i>Cardiovascular Research</i> , 2018, 114, 1871-1882.	1.8	38
292	Telomere length and outcome in heart failure. <i>Annals of Medicine</i> , 2010, 42, 36-44.	1.5	37
293	Depressive symptoms and inflammation in patients hospitalized for heart failure. <i>American Heart Journal</i> , 2011, 161, 1053-1059.	1.2	37
294	Omecamtiv mecarbil: a new cardiac myosin activator for the treatment of heart failure. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 117-127.	1.9	37
295	Conceptual Considerations for Device-Based Therapy in Acute Decompensated Heart Failure. <i>Circulation: Heart Failure</i> , 2020, 13, e006731.	1.6	37
296	Renal Hemodynamic Effects of Serelaxin in Patients With Chronic Heart Failure. <i>Circulation: Heart Failure</i> , 2014, 7, 994-1002.	1.6	36
297	The clinical course of health status and association with outcomes in patients hospitalized for heart failure: insights from ASCEND-HF. <i>European Journal of Heart Failure</i> , 2016, 18, 306-313.	2.9	36
298	Accumulation of 5-oxoproline in myocardial dysfunction and the protective effects of OPLAH. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	36
299	Mild renal dysfunction is associated with electrocardiographic left ventricular hypertrophy. <i>American Journal of Hypertension</i> , 2005, 18, 342-347.	1.0	35
300	Diabetes: a driver for heart failure. <i>Heart</i> , 2011, 97, 774-780.	1.2	35
301	Comparative Assessment of Short-Term Adverse Events in Acute Heart Failure With Cystatin C and Other Estimates of Renal Function. <i>JACC: Heart Failure</i> , 2015, 3, 40-49.	1.9	35
302	Combining Diuretic Response and Hemoconcentration to Predict Rehospitalization After Admission for Acute Heart Failure. <i>Circulation: Heart Failure</i> , 2016, 9, .	1.6	35
303	MicroRNAs relate to early worsening of renal function in patients with acute heart failure. <i>International Journal of Cardiology</i> , 2016, 203, 564-569.	0.8	35
304	Biomarker-Guided Versus Guideline-Based Treatment of Patients With Heart Failure. <i>Journal of the American College of Cardiology</i> , 2018, 71, 386-398.	1.2	35
305	Vericiguat in patients with atrial fibrillation and heart failure with reduced ejection fraction: insights from the VICTORIA trial. <i>European Journal of Heart Failure</i> , 2021, 23, 1300-1312.	2.9	35
306	Creatinine excretion rate, a marker of muscle mass, is related to clinical outcome in patients with chronic systolic heart failure. <i>Clinical Research in Cardiology</i> , 2014, 103, 976-983.	1.5	34

#	ARTICLE	IF	CITATIONS
307	Procalcitonin-based indication of bacterial infection identifies high risk acute heart failure patients. <i>International Journal of Cardiology</i> , 2016, 204, 164-171.	0.8	34
308	Plasma biomarkers to predict or rule out early post-discharge events after hospitalization for acute heart failure. <i>European Journal of Heart Failure</i> , 2017, 19, 728-738.	2.9	34
309	Clinical and Hemodynamic Correlates and Prognostic Value of VE/VCO <sub>2</sub> Slope in Patients With Heart Failure With Preserved Ejection Fraction and Pulmonary Hypertension. <i>Journal of Cardiac Failure</i> , 2017, 23, 777-782.	0.7	34
310	Safety, Tolerability and efficacy of Rapid Optimization, helped by NT-proBNP and GDF-15, of Heart Failure therapies (STRONG-HF): rationale and design for a multicentre, randomized, parallel-group study. <i>European Journal of Heart Failure</i> , 2019, 21, 1459-1467.	2.9	34
311	Worsening renal function in acute heart failure in the context of diuretic response. <i>European Journal of Heart Failure</i> , 2022, 24, 365-374.	2.9	34
312	Rationale and Design of the VITALITY-HFpEF Trial. <i>Circulation: Heart Failure</i> , 2019, 12, e005998.	1.6	33
313	Clinical value of pre-discharge bioadrenomedullin as a marker of residual congestion and high risk of heart failure hospital readmission. <i>European Journal of Heart Failure</i> , 2020, 22, 683-691.	2.9	33
314	Neutrophil-to-lymphocyte ratio and outcomes in patients with new-onset or worsening heart failure with reduced and preserved ejection fraction. <i>ESC Heart Failure</i> , 2021, 8, 3168-3179.	1.4	33
315	Novel biomarker-driven prognostic models to predict morbidity and mortality in chronic heart failure: the EMPEROR-Reduced trial. <i>European Heart Journal</i> , 2021, 42, 4455-4464.	1.0	33
316	Nebivolol: third-generation $\beta$ -blockade. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 1539-1550.	0.9	32
317	Clustering of 37 circulating biomarkers by exploratory factor analysis in patients following complicated acute myocardial infarction. <i>International Journal of Cardiology</i> , 2013, 166, 729-735.	0.8	32
318	Plasma kidney injury molecule-1 in heart failure: renal mechanisms and clinical outcome. <i>European Journal of Heart Failure</i> , 2016, 18, 641-649.	2.9	32
319	A combined clinical and biomarker approach to predict diuretic response in acute heart failure. <i>Clinical Research in Cardiology</i> , 2016, 105, 145-153.	1.5	32
320	Effect of Sotagliflozin on Total Hospitalizations in Patients With Type 2 Diabetes and Worsening Heart Failure. <i>Annals of Internal Medicine</i> , 2021, 174, 1065-1072.	2.0	32
321	Impact of mitral regurgitation in patients with worsening heart failure: insights from <sc>BIOSTAT-CHF</sc>. <i>European Journal of Heart Failure</i> , 2021, 23, 1750-1758.	2.9	32
322	Addition of an angiotensin receptor blocker to full-dose ACE-inhibition: controversial or common sense? The opinions expressed in this article are not necessarily those of the Editors of the <i>European Heart Journal</i> or of the <i>European Society of Cardiology</i> . <i>European Heart Journal</i> , 2005, 26, 2361-2367.	1.0	31
323	Urinary Proteins in Heart Failure. <i>Progress in Cardiovascular Diseases</i> , 2012, 55, 44-55.	1.6	31
324	Hemodialysis-Induced Regional Left Ventricular Systolic Dysfunction and Inflammation: A Cross-sectional Study. <i>American Journal of Kidney Diseases</i> , 2014, 64, 265-273.	2.1	31

#	ARTICLE	IF	CITATIONS
325	Bioâ€œadrenomedullin as a potential quick, reliable, and objective marker of congestion in heart failure. <i>European Journal of Heart Failure</i> , 2018, 20, 1363-1365.	2.9	31
326	Time to rename the middle child of heart failure: heart failure with mildly reduced ejection fraction. <i>European Heart Journal</i> , 2020, 41, 2353-2355.	1.0	31
327	Early treatment with tolvaptan improves diuretic response in acute heart failure with renal dysfunction. <i>Clinical Research in Cardiology</i> , 2017, 106, 802-812.	1.5	30
328	Clinical Correlates and Prognostic Value of Proenkephalin in Acute and Chronic Heart Failure. <i>Journal of Cardiac Failure</i> , 2017, 23, 231-239.	0.7	30
329	Proteomic diversity of highâ€œdensity lipoprotein explains its association with clinical outcome in patients with heart failure. <i>European Journal of Heart Failure</i> , 2018, 20, 260-267.	2.9	30
330	Dynamics of cerebral blood flow in patients with mild nonâ€œischaemic heart failure. <i>European Journal of Heart Failure</i> , 2017, 19, 261-268.	2.9	29
331	Sudden cardiac death after acute heart failure hospital admission: insights from ASCENDâ€œHF. <i>European Journal of Heart Failure</i> , 2018, 20, 525-532.	2.9	29
332	$\hat{\rho}^2 <sub>1 </sub>$ -Adrenoreceptor Autoantibodies in Heart Failure. <i>Circulation: Heart Failure</i> , 2020, 13, e006155.	1.6	29
333	The influence of atrial fibrillation on the levels of NT-proBNP versus GDF-15 in patients with heart failure. <i>Clinical Research in Cardiology</i> , 2020, 109, 331-338.	1.5	28
334	Plasma proteomic approach in patients with heart failure: insights into pathogenesis of disease progression and potential novel treatment targets. <i>European Journal of Heart Failure</i> , 2020, 22, 70-80.	2.9	28
335	A network analysis to identify pathophysiological pathways distinguishing ischaemic from nonâ€œischaemic heart failure. <i>European Journal of Heart Failure</i> , 2020, 22, 821-833.	2.9	28
336	Effect of very early angiotensin-converting enzyme inhibition on left ventricular dilation after myocardial infarction in patients receiving thrombolysis. <i>Journal of the American College of Cardiology</i> , 2000, 36, 2047-2053.	1.2	27
337	Long-term tricuspid valve prosthesis-related complications in patients with congenital heart disease. <i>European Journal of Cardio-thoracic Surgery</i> , 2014, 45, 83-89.	0.6	27
338	Rationale and design of the phase 2b clinical trials to study the effects of the partial adenosine A1â€œreceptor agonist neladenoson bialanate in patients with chronic heart failure with reduced (PANTHEON) and preserved (PANACHE) ejection fraction. <i>European Journal of Heart Failure</i> , 2018, 20, 1601-1610.	2.9	27
339	Safety and efficacy of the partial adenosine A1 receptor agonist neladenoson bialanate in patients with chronic heart failure with reduced ejection fraction: a phase IIb, randomized, doubleâ€œblind, placeboâ€œcontrolled trial. <i>European Journal of Heart Failure</i> , 2019, 21, 1426-1433.	2.9	27
340	The burden of nonâ€œcardiac comorbidities and association with clinical outcomes in an acute heart failure trialâ€œâ€œInsights from ASCENDâ€œHF. <i>European Journal of Heart Failure</i> , 2020, 22, 1022-1031.	2.9	27
341	Long-term results after successful percutaneous transluminal coronary angioplasty in patients over 75 years of age. <i>American Journal of Cardiology</i> , 1996, 77, 690-695.	0.7	26
342	Vitamin B12 and folate deficiency in chronic heart failure. <i>Heart</i> , 2015, 101, 302-310.	1.2	26

#	ARTICLE	IF	CITATIONS
343	Geographic Differences in Patients in a Global Acute Heart Failure Clinical Trial (from the ASCEND-HF) Tj ETQq1 1 0.784314 rgBT /Ove	0.7	26
344	Progression of Renal Impairment and Chronic Kidney Disease in Chronic Heart Failure: An Analysis From GISSI-HF. <i>Journal of Cardiac Failure</i> , 2017, 23, 2-9.	0.7	26
345	Transitioning from usual care to biomarker-based personalized and precision medicine in heart failure: call for action. <i>European Heart Journal</i> , 2018, 39, 2793-2799.	1.0	26
346	Hyperkalemia and Treatment With RAAS Inhibitors During Acute Heart Failure Hospitalizations and Their Association With Mortality. <i>JACC: Heart Failure</i> , 2019, 7, 970-979.	1.9	26
347	Quality of life in men and women with heart failure: association with outcome, and comparison between the Kansas City Cardiomyopathy Questionnaire and the EuroQol 5 dimensions questionnaire. <i>European Journal of Heart Failure</i> , 2021, 23, 567-577.	2.9	26
348	Natriuresis-guided therapy in acute heart failure: rationale and design of the <sc>Pragmatic Urinary Sodium-based treatment algorithm</sc> in <sc>Acute Heart Failure</sc> (<sc>PUSH-AHF</sc>) trial. <i>European Journal of Heart Failure</i> , 2022, 24, 385-392.	2.9	26
349	Epicardial adipose tissue related to left atrial and ventricular function in heart failure with preserved versus reduced and mildly reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2022, 24, 1346-1356.	2.9	26
350	Anemia in chronic heart failure: etiology and treatment options. <i>Current Opinion in Cardiology</i> , 2008, 23, 141-147.	0.8	25
351	Low pulse pressure is an independent predictor of mortality and morbidity in non ischaemic, but not in ischaemic advanced heart failure patients. <i>International Journal of Cardiology</i> , 2009, 131, 336-344.	0.8	25
352	Geographical location affects the levels and association of trimethylamine N-oxide with heart failure mortality in BIOSTAT-HF: a post-hoc analysis. <i>European Journal of Heart Failure</i> , 2019, 21, 1291-1294.	2.9	25
353	Clinical correlates and outcome associated with changes in 6-minute walking distance in patients with heart failure: findings from the BIOSTAT-HF study. <i>European Journal of Heart Failure</i> , 2019, 21, 218-226.	2.9	25
354	Distinct Pathological Pathways in Patients With Heart Failure and Diabetes. <i>JACC: Heart Failure</i> , 2020, 8, 234-242.	1.9	25
355	Rodent heart failure models do not reflect the human circulating microRNA signature in heart failure. <i>PLoS ONE</i> , 2017, 12, e0177242.	1.1	25
356	Early vs. late worsening heart failure during acute heart failure hospitalization: insights from the PROTECT trial. <i>European Journal of Heart Failure</i> , 2015, 17, 697-706.	2.9	24
357	Partial Adenosine A1 Agonist in Heart Failure. <i>Handbook of Experimental Pharmacology</i> , 2016, 243, 177-203.	0.9	24
358	Effects of serelaxin in patients admitted for acute heart failure: a meta-analysis. <i>European Journal of Heart Failure</i> , 2020, 22, 315-329.	2.9	24
359	The role of cathepsin D in the pathophysiology of heart failure and its potentially beneficial properties: a translational approach. <i>European Journal of Heart Failure</i> , 2020, 22, 2102-2111.	2.9	24
360	Effects of combined renin-angiotensin-aldosterone system inhibitor and beta-blocker treatment on outcomes in heart failure with reduced ejection fraction: insights from <sc>BIOSTAT-HF</sc> and <sc>ASIAN-HF</sc> registries. <i>European Journal of Heart Failure</i> , 2020, 22, 1472-1482.	2.9	24

#	ARTICLE	IF	CITATIONS
361	Prognostic Role of Prior Heart Failure Hospitalization Among Patients Hospitalized for Worsening Chronic Heart Failure. <i>Circulation: Heart Failure</i> , 2021, 14, e007871.	1.6	24
362	Angiotensin II formation in human vasculature after chronic ACE inhibition: a prospective, randomized, placebo-controlled study. QUO VADIS Investigators. <i>Cardiovascular Drugs and Therapy</i> , 2000, 14, 55-60.	1.3	23
363	The potential role of valsartan + AHU377 (LCZ696) in the treatment of heart failure. <i>Expert Opinion on Investigational Drugs</i> , 2013, 22, 1041-1047.	1.9	23
364	Comparative effectiveness of torsemide versus furosemide in heart failure patients: insights from the PROTECT trial. <i>Future Cardiology</i> , 2015, 11, 585-595.	0.5	23
365	Identification of novel biomarkers in plasma for prediction of treatment response in patients with heart failure. <i>Lancet, The</i> , 2015, 385, S26.	6.3	23
366	Proenkephalin, an Opioid System Surrogate, as a Novel Comprehensive Renal Marker in Heart Failure. <i>Circulation: Heart Failure</i> , 2019, 12, e005544.	1.6	23
367	Plasma Angiotensin-Converting Enzyme Activity and Left Ventricular Dilation After Myocardial Infarction. <i>Circulation</i> , 1997, 95, 2607-2609.	1.6	23
368	Loop diuretic dose adjustments after a hospitalization for heart failure: insights from ASCEND-HF. <i>European Journal of Heart Failure</i> , 2015, 17, 340-346.	2.9	22
369	Rate pressure product and the components of heart rate and systolic blood pressure in hospitalized heart failure patients with preserved ejection fraction: Insights from ASCEND-HF. <i>Clinical Cardiology</i> , 2018, 41, 945-952.	0.7	22
370	Hepatorenal dysfunction identifies high-risk patients with acute heart failure: insights from the RELAX-AHF trial. <i>ESC Heart Failure</i> , 2019, 6, 1188-1198.	1.4	22
371	Chloride in Heart Failure. <i>JACC: Heart Failure</i> , 2021, 9, 904-915.	1.9	22
372	Correlates of B-type natriuretic peptide and 6-min walk in heart failure patients. <i>International Journal of Cardiology</i> , 2006, 108, 63-67.	0.8	21
373	Advanced glycation end-products, anti-hypertensive treatment and diastolic function in patients with hypertension and diastolic dysfunction. <i>European Journal of Heart Failure</i> , 2010, 12, 397-403.	2.9	21
374	A Novel Approach to Drug Development in Heart Failure: Towards Personalized Medicine. <i>Canadian Journal of Cardiology</i> , 2014, 30, 288-295.	0.8	21
375	Relationship between left ventricular ejection fraction and cardiovascular outcomes following hospitalization for heart failure: insights from the RELAX-AHF2 trial. <i>European Journal of Heart Failure</i> , 2020, 22, 726-738.	2.9	21
376	Hemoglobin and Clinical Outcomes in the Vericiguat Global Study in Patients With Heart Failure and Reduced Ejection Fraction (VICTORIA). <i>Circulation</i> , 2021, 144, 1489-1499.	1.6	21
377	Vascular Function and Mild Renal Impairment in Stable Coronary Artery Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2006, 26, 379-384.	1.1	20
378	Functional and Hemodynamic Cardiac Determinants of Exercise Capacity in Patients With Systolic Heart Failure. <i>American Journal of Cardiology</i> , 2012, 110, 1336-1341.	0.7	20

#	ARTICLE	IF	CITATIONS
379	Changes in Left Ventricular Diastolic Function During Hemodialysis Sessions. <i>American Journal of Kidney Diseases</i> , 2013, 62, 549-556.	2.1	20
380	Rationale and design for the development of a novel nitroxyl donor in patients with acute heart failure. <i>European Journal of Heart Failure</i> , 2019, 21, 1022-1031.	2.9	20
381	Heart failure treatment up-titration and outcome and age: an analysis of BIOSTAT-CHF. <i>European Journal of Heart Failure</i> , 2021, 23, 436-444.	2.9	20
382	Higher doses of loop diuretics limit up-titration of angiotensin-converting enzyme inhibitors in patients with heart failure and reduced ejection fraction. <i>Clinical Research in Cardiology</i> , 2020, 109, 1048-1059.	1.5	20
383	Additional burden of iron deficiency in heart failure patients beyond the cardio-renal anaemia syndrome: findings from the <sc>BIOSTAT-CHF</sc> study. <i>European Journal of Heart Failure</i> , 2022, 24, 192-204.	2.9	20
384	Usefulness of Preoperative C-Reactive Protein and Soluble Intercellular Adhesion Molecule-1 Level for Predicting Future Cardiovascular Events After Coronary Artery Bypass Grafting. <i>American Journal of Cardiology</i> , 2006, 97, 1697-1701.	0.7	19
385	Anaemia is associated with shorter leucocyte telomere length in patients with chronic heart failure. <i>European Journal of Heart Failure</i> , 2010, 12, 348-353.	2.9	19
386	Circulating Kidney Injury Molecule-1 Levels in Acute Heart Failure. <i>JACC: Heart Failure</i> , 2015, 3, 777-785.	1.9	19
387	Is acute heart failure a distinctive disorder? An analysis from BIOSTAT-CHF. <i>European Journal of Heart Failure</i> , 2021, 23, 43-57.	2.9	19
388	Spironolactone in Patients With Heart Failure, Preserved Ejection Fraction, and Worsening Renal Function. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1211-1221.	1.2	19
389	Renin-Angiotensin System Intervention to Prevent In-Stent Restenosis. <i>Journal of Cardiovascular Pharmacology</i> , 2005, 45, 88-98.	0.8	18
390	Effect of Withdrawal of Pravastatin Therapy on C-Reactive Protein and Low-Density Lipoprotein Cholesterol. <i>American Journal of Cardiology</i> , 2007, 100, 1548-1551.	0.7	18
391	Renal Function Dependent Association of AGTR1 Polymorphism (A1166C) and Electrocardiographic Left-Ventricular Hypertrophy. <i>American Journal of Hypertension</i> , 2007, 20, 1097-1103.	1.0	18
392	Hemoglobin levels and new-onset heart failure in the community. <i>American Heart Journal</i> , 2015, 169, 94-101.e2.	1.2	18
393	Very Early Diuretic Response After Admission for Acute Heart Failure. <i>Journal of Cardiac Failure</i> , 2019, 25, 12-19.	0.7	18
394	Is Anemia in Chronic Heart Failure Caused by Iron Deficiency?. <i>Journal of the American College of Cardiology</i> , 2007, 49, 2301-2302.	1.2	17
395	Ischemic patterns assessed by positron emission tomography predict adverse outcome in patients with idiopathic dilated cardiomyopathy. <i>Journal of Nuclear Cardiology</i> , 2009, 16, 769-774.	1.4	17
396	Why do drugs for acute heart failure fail?. <i>European Journal of Heart Failure</i> , 2012, 14, 955-956.	2.9	17

#	ARTICLE	IF	CITATIONS
397	Long-term changes in renal function and perfusion in heart failure patients with reduced ejection fraction. <i>Clinical Research in Cardiology</i> , 2016, 105, 10-16.	1.5	17
398	Sex differences in early dyspnea relief between men and women hospitalized for acute heart failure: insights from the RELAX-AHF study. <i>Clinical Research in Cardiology</i> , 2017, 106, 280-292.	1.5	17
399	Dual Vasopressin Receptor Antagonism to Improve Congestion in Patients With Acute Heart Failure: Design of the AVANTI Trial. <i>Journal of Cardiac Failure</i> , 2021, 27, 233-241.	0.7	17
400	Effects of a Novel Nitroxyl Donor in Acute Heart Failure. <i>JACC: Heart Failure</i> , 2021, 9, 146-157.	1.9	17
401	Predictors of Angiotensin-Converting Enzyme Inhibitor-Induced Reduction of Urinary Albumin Excretion in Nondiabetic Patients. <i>Hypertension</i> , 2006, 48, 870-876.	1.3	16
402	Predictive value of tissue Doppler imaging for left ventricular ejection fraction, remodelling, and infarct size after percutaneous coronary intervention for acute myocardial infarction. <i>European Journal of Echocardiography</i> , 2010, 11, 596-601.	2.3	16
403	Effect of additive renin inhibition with aliskiren on renal blood flow in patients with Chronic Heart Failure and Renal Dysfunction (Additive Renin Inhibition with Aliskiren on renal blood flow and) <i>Tj ETQq1 1 0.784314 rgBT /Overlock 10</i> <i>Heart Journal</i> , 2015, 169, 693-701.e3.	1.2	16
404	Fibroblast growth factor 23 correlates with volume status in haemodialysis patients and is not reduced by haemodialysis. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 1494-1501.	0.4	16
405	Effects of serelaxin in acute heart failure patients with renal impairment: results from RELAX-AHF. <i>Clinical Research in Cardiology</i> , 2016, 105, 727-737.	1.5	16
406	Coronary angiography in worsening heart failure: determinants, findings and prognostic implications. <i>Heart</i> , 2018, 104, 606-613.	1.2	16
407	Relation of Volume Overload to Clinical Outcomes in Acute Heart Failure (From ASCEND-HF). <i>American Journal of Cardiology</i> , 2018, 122, 1506-1512.	0.7	16
408	Trajectories of Changes in Renal Function in Patients with Acute Heart Failure. <i>Journal of Cardiac Failure</i> , 2019, 25, 866-874.	0.7	16
409	Genetic Associations With Plasma Angiotensin Converting Enzyme 2 Concentration. <i>Circulation</i> , 2020, 142, 1117-1119.	1.6	16
410	A Clinical Tool to Predict Low Serum Selenium in Patients with Worsening Heart Failure. <i>Nutrients</i> , 2020, 12, 2541.	1.7	16
411	Interleukin-6 and Outcomes in Acute Heart Failure: An ASCEND-HF Substudy. <i>Journal of Cardiac Failure</i> , 2021, 27, 670-676.	0.7	16
412	Vascular effects of quinapril completely depend on ACE insertion/deletion polymorphism. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2004, 5, 130-134.	1.0	15
413	Vascular Response to Angiotensin II Predicts Long-Term Prognosis in Patients Undergoing Coronary Artery Bypass Grafting. <i>Hypertension</i> , 2004, 44, 930-934.	1.3	15
414	Ventricular dysfunction in a family with long QT syndrome type 3. <i>Europace</i> , 2013, 15, 1516-1521.	0.7	15



#	ARTICLE	IF	CITATIONS
415	Influence of Clinical Trial Site Enrollment on Patient Characteristics, Protocol Completion, and End Points. <i>Circulation: Heart Failure</i> , 2016, 9, .	1.6	15
416	Genetic risk and atrial fibrillation in patients with heart failure. <i>European Journal of Heart Failure</i> , 2020, 22, 519-527.	2.9	15
417	Cardiovascular and non-cardiovascular death distinction: the utility of troponin beyond N-terminal pro-B-type natriuretic peptide. Findings from the BIOSTAT-CHF study. <i>European Journal of Heart Failure</i> , 2020, 22, 81-89.	2.9	15
418	Men more vulnerable to COVID-19: explained by ACE2 on the X chromosome?. <i>European Heart Journal</i> , 2020, 41, 3096-3096.	1.0	15
419	The value of spot urinary creatinine as a marker of muscle wasting in patients with new-onset or worsening heart failure. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2021, 12, 555-567.	2.9	15
420	Non-adherence to heart failure medications predicts clinical outcomes: assessment in a single spot urine sample by liquid chromatography-tandem mass spectrometry (results of a prospective) <i>Overlock 10 Tf 50 3</i>	0.0	0
421	Dyslipidemia and endothelium-dependent relaxation in internal mammary arteries used for coronary bypass surgery. <i>Cardiovascular Research</i> , 1997, 34, 568-574.	1.8	14
422	Progression of atherosclerosis after venous coronary artery bypass graft surgery: A 15-year follow-up study. , 1997, 41, 141-150.		14
423	β-Adrenoceptor Antagonists in Elderly Patients with Heart Failure. <i>Drugs and Aging</i> , 2007, 24, 1031-1044.	1.3	14
424	HFrEF vs. HFpEF: can microRNAs advance the diagnosis?. <i>European Journal of Heart Failure</i> , 2015, 17, 351-354.	2.9	14
425	Diabetes Mellitus and Right Ventricular Dysfunction in Heart Failure With Preserved Ejection Fraction. <i>American Journal of Cardiology</i> , 2018, 121, 621-627.	0.7	14
426	Pregnancy After Biventricular Repair for Pulmonary Atresia With Ventricular Septal Defect. <i>American Journal of Cardiology</i> , 2006, 98, 262-266.	0.7	13
427	Excellent Long-Term Clinical Outcome After Coronary Artery Bypass Surgery Using Three Pedicled Arterial Grafts in Patients With Three-Vessel Disease. <i>Annals of Thoracic Surgery</i> , 2008, 85, 508-512.	0.7	13
428	Erythropoietin levels in heart failure after an acute myocardial infarction: Determinants, prognostic value, and the effects of captopril versus losartan. <i>American Heart Journal</i> , 2009, 157, 91-96.	1.2	13
429	Renal dysfunction in heart failure with a preserved ejection fraction: cause or consequence?. <i>European Journal of Heart Failure</i> , 2016, 18, 113-114.	2.9	13
430	High serum erythropoietin levels are related to heart failure development in subjects from the general population with albuminuria: data from PREVEND. <i>European Journal of Heart Failure</i> , 2016, 18, 814-821.	2.9	13
431	Relationship Between Enrolling Country Income Level and Patient Profile, Protocol Completion, and Trial End Points. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2018, 11, e004783.	0.9	13
432	Haemodynamic effects of the nitroxyl donor cimlanod (BMS-986231) in chronic heart failure: a randomized trial. <i>European Journal of Heart Failure</i> , 2021, 23, 1147-1155.	2.9	13

#	ARTICLE	IF	CITATIONS
433	Cost Effectiveness of Angiotensin Receptor Blocker Monotherapy in Patients with Hypertension in the Netherlands. <i>American Journal of Cardiovascular Drugs</i> , 2010, 10, 49-54.	1.0	12
434	Long Term Effects of Epoetin Alfa in Patients with ST- Elevation Myocardial Infarction. <i>Cardiovascular Drugs and Therapy</i> , 2013, 27, 433-439.	1.3	12
435	Heart failure etiologies and clinical factors precipitating for worsening heart failure: Findings from BIOSTAT-CHF. <i>European Journal of Internal Medicine</i> , 2020, 71, 62-69.	1.0	12
436	Cause of Death in Patients With Acute Heart Failure. <i>JACC: Heart Failure</i> , 2020, 8, 999-1008.	1.9	12
437	The Effect of Metformin on Diastolic Function in Patients Presenting with ST-Elevation Myocardial Infarction. <i>PLoS ONE</i> , 2016, 11, e0168340.	1.1	12
438	Left atrial structure and function in heart failure with reduced (HF <sub>r</sub> EF) versus preserved ejection fraction (HF <sub>p</sub> EF): systematic review and meta-analysis. <i>Heart Failure Reviews</i> , 2022, 27, 1933-1955.	1.7	12
439	An economic assessment of losartan-based versus atenolol-based therapy in patients with hypertension and left-ventricular hypertrophy: Results from the losartan intervention for endpoint reduction (LIFE) study adapted to The Netherlands. <i>Clinical Therapeutics</i> , 2007, 29, 963-971.	1.1	11
440	Erythropoietin in Chronic Heart Failure. <i>Congestive Heart Failure</i> , 2007, 13, 289-292.	2.0	11
441	Low pulse pressure as a poor-man's indicator of a low cardiac index in patients with severe cardiac dysfunction. <i>Journal of Cardiovascular Medicine</i> , 2014, 15, 315-321.	0.6	11
442	Acute heart failure in the young: Clinical characteristics and biomarker profiles. <i>International Journal of Cardiology</i> , 2016, 221, 1067-1072.	0.8	11
443	Associations of Body Mass Index With Laboratory and Biomarkers in Patients With Acute Heart Failure. <i>Circulation: Heart Failure</i> , 2017, 10, .	1.6	11
444	Markers of left ventricular systolic dysfunction when left ventricular ejection fraction is normal. <i>European Journal of Heart Failure</i> , 2018, 20, 1636-1638.	2.9	11
445	Effect of isolated ultrafiltration and isovolemic dialysis on myocardial perfusion and left ventricular function assessed with <sup>13</sup> N-NH <sub>3</sub> positron emission tomography and echocardiography. <i>American Journal of Physiology - Renal Physiology</i> , 2018, 314, F445-F452.	1.3	11
446	Prognostic Implications of Changes in Amino-Terminal Pro-B-Type Natriuretic Peptide in Acute Decompensated Heart Failure: Insights From ASCEND-HF. <i>Journal of Cardiac Failure</i> , 2019, 25, 703-711.	0.7	11
447	Mega-trials in heart failure: effects of dilution in examination of new therapies. <i>European Journal of Heart Failure</i> , 2020, 22, 1698-1707.	2.9	11
448	Association between up-titration of medical therapy and total hospitalizations and mortality in patients with recent worsening heart failure across the ejection fraction spectrum. <i>European Journal of Heart Failure</i> , 2021, 23, 1170-1181.	2.9	11
449	Iron deficiency contributes to resistance to endogenous erythropoietin in anaemic heart failure patients. <i>European Journal of Heart Failure</i> , 2021, 23, 1677-1686.	2.9	11
450	Temporal Trends and Clinical Trial Characteristics Associated With the Inclusion of Women in Heart Failure Trial Steering Committees: A Systematic Review. <i>Circulation: Heart Failure</i> , 2021, 14, e008064.	1.6	11

#	ARTICLE	IF	CITATIONS
451	The genomics of heart failure: design and rationale of the HERMES consortium. <i>ESC Heart Failure</i> , 2021, 8, 5531-5541.	1.4	11
452	Sex-Specific Clinical Outcomes of the PACT-HF Randomized Trial. <i>Circulation: Heart Failure</i> , 2021, 14, e008548.	1.6	11
453	The Current Role of ACE-inhibitors for Secondary Prevention in Cardiovascular Disease; from Pathogenesis to Clinical Practice. <i>Cardiovascular Drugs and Therapy</i> , 2006, 20, 69-73.	1.3	10
454	Fertility, Pregnancy, and Delivery After Biventricular Repair for Pulmonary Atresia With an Intact Ventricular Septum. <i>American Journal of Cardiology</i> , 2006, 98, 259-261.	0.7	10
455	Aortic valve prosthesisâ€“patient mismatch and exercise capacity in adult patients with congenital heart disease. <i>Heart</i> , 2016, 102, 107-113.	1.2	10
456	Clinical and prognostic value of spot urinary creatinine in chronic heart failureâ€”An analysis from GISSI-HF. <i>American Heart Journal</i> , 2017, 188, 189-195.	1.2	10
457	Prognostic significance of changes in heart rate following uptitration of beta-blockers in patients with sub-optimally treated heart failure with reduced ejection fraction in sinus rhythm versus atrial fibrillation. <i>Clinical Research in Cardiology</i> , 2019, 108, 797-805.	1.5	10
458	A combined bioinformatics, experimental and clinical approach to identify novel cardiacâ€“specific heart failure biomarkers: is Dickkopf â€“3 ( DKK3 ) a possible candidate?. <i>European Journal of Heart Failure</i> , 2020, 22, 2065-2074.	2.9	10
459	Association of left ventricular ejection fraction with worsening renal function in patients with acute heart failure: insights from the <scp>RELAXâ€“AHF</scp>â€“2 study. <i>European Journal of Heart Failure</i> , 2021, 23, 58-67.	2.9	10
460	Multimarker profiling identifies protective and harmful immune processes in heart failure: findings from BIostat-CHF. <i>Cardiovascular Research</i> , 2022, 118, 1964-1977.	1.8	10
461	Clinical impact of changes in mitral regurgitation severity after medical therapy optimization in heart failure. <i>Clinical Research in Cardiology</i> , 2022, 111, 912-923.	1.5	10
462	Improving clinical trial efficiency using a machine learningâ€“based risk score to enrich study populations. <i>European Journal of Heart Failure</i> , 2022, 24, 1418-1426.	2.9	10
463	Distinct pathophysiological pathways in women and men with heart failure. <i>European Journal of Heart Failure</i> , 2022, 24, 1532-1544.	2.9	10
464	Usefulness of hypertriglyceridemia in predicting myocardial infarction late after coronary artery bypass operation. <i>American Journal of Cardiology</i> , 1997, 79, 1350-1354.	0.7	9
465	Functional antagonism of different angiotensin II type I receptor blockers in human arteries. <i>Cardiovascular Drugs and Therapy</i> , 2002, 16, 311-316.	1.3	9
466	Differences Between Angiotensin-Converting Enzyme Inhibition and Angiotensin II-AT1 Antagonism on Angiotensin-Mediated Responses in Human Internal Mammary Arteries. <i>Journal of Cardiovascular Pharmacology</i> , 2003, 41, 178-184.	0.8	9
467	Acute Administration of Angiotensin Converting Enzyme Inhibitors in Thrombolysed Myocardial Infarction Patients Is Associated with a Decreased Incidence of Heart Failure, but an Increased Re-Infarction Risk. <i>Cardiovascular Drugs and Therapy</i> , 2005, 19, 119-124.	1.3	9
468	Therapeutic potential of erythropoietin in cardiovascular disease: Erythropoiesis and beyond. <i>Current Heart Failure Reports</i> , 2007, 4, 127-133.	1.3	9

#	ARTICLE	IF	CITATIONS
469	Unsolved challenges in diuretic therapy for acute heart failure: a focus on diuretic response. Expert Review of Cardiovascular Therapy, 2015, 13, 1075-1078.	0.6	9
470	Day vs night: Does time of presentation matter in acute heart failure? A secondary analysis from the RELAX-AHF trial. American Heart Journal, 2017, 187, 62-69.	1.2	9
471	Atrial Fibrillation in Heart Failure —. JACC: Heart Failure, 2017, 5, 575-577.	1.9	9
472	Circulating Cardiac Troponin I Levels Measured by a Novel Highly Sensitive Assay in Acute Decompensated Heart Failure: Insights From the ASCEND-HF Trial. Journal of Cardiac Failure, 2018, 24, 512-519.	0.7	9
473	Is plasma renin activity associated with worse outcomes in acute heart failure? A secondary analysis from the BLAST-AHF trial. European Journal of Heart Failure, 2019, 21, 1561-1570.	2.9	9
474	Clinical determinants and prognostic implications of renin and aldosterone in patients with symptomatic heart failure. ESC Heart Failure, 2020, 7, 953-963.	1.4	9
475	Dipeptidyl peptidase 3, a marker of the antagonist pathway of the renin-angiotensin-aldosterone system in patients with heart failure. European Journal of Heart Failure, 2021, 23, 947-953.	2.9	9
476	Impaired High-Density Lipoprotein Function in Patients With Heart Failure. Journal of the American Heart Association, 2021, 10, e019123.	1.6	9
477	Post-transplant inotrope score is associated with clinical outcomes after adult heart transplantation. Clinical Transplantation, 2021, 35, e14347.	0.8	9
478	Dosing of losartan in men versus women with heart failure with reduced ejection fraction: the HEAAL trial. European Journal of Heart Failure, 2021, 23, 1477-1484.	2.9	9
479	Risk and risk reduction in trials of heart failure with reduced ejection fraction: absolute or relative?. European Journal of Heart Failure, 2021, 23, 1437-1444.	2.9	9
480	Pathophysiological pathways related to high plasma growth differentiation factor 15 concentrations in patients with heart failure. European Journal of Heart Failure, 2022, 24, 308-320.	2.9	9
481	A First-in-Human Study of AMG 986, a Novel Apelin Receptor Agonist, in Healthy Subjects and Heart Failure Patients. Cardiovascular Drugs and Therapy, 2023, 37, 743-755.	1.3	9
482	Effects of C-Reactive Protein and Cholesterol on Responsiveness In Vitro of the Internal Thoracic Artery to Angiotensin II in Patients Having Coronary Artery Bypass Grafting. American Journal of Cardiology, 2006, 98, 751-753.	0.7	8
483	Comparison of Cardiac Positron Emission Tomography Perfusion Defects During Stress Induced by Hemodialysis Versus Adenosine. American Journal of Kidney Diseases, 2012, 59, 862-864.	2.1	8
484	Identifying Subpopulations with Distinct Response to Treatment Using Plasma Biomarkers in Acute Heart Failure: Results from the PROTECT Trial. Cardiovascular Drugs and Therapy, 2017, 31, 281-293.	1.3	8
485	N-terminal pro-B-type natriuretic peptide and prognosis in Caucasian vs. Asian patients with heart failure. ESC Heart Failure, 2018, 5, 279-287.	1.4	8
486	Circulating plasma angiotensin-converting enzyme 2 concentration is elevated in patients with kidney disease and diabetes. European Heart Journal, 2020, 41, 3099-3099.	1.0	8

#	ARTICLE	IF	CITATIONS
487	Differences in biomarkers and molecular pathways according to age for patients with HFrEF. <i>Cardiovascular Research</i> , 2021, 117, 2228-2236.	1.8	8
488	Amended <sc>STRONG&#x2013;HF</sc> study design. <i>European Journal of Heart Failure</i> , 2021, 23, 1981-1982.	2.9	8
489	Developments in Exercise Capacity Assessment in Heart Failure Clinical Trials and the Rationale for the Design of METEORIC-HF. <i>Circulation: Heart Failure</i> , 2022, 15, CIRCHEARTFAILURE121008970.	1.6	8
490	Clinical implications of left atrial changes after optimization of medical therapy in patients with heart failure. <i>European Journal of Heart Failure</i> , 2022, 24, 2131-2139.	2.9	8
491	Tackling Early Heart Failure Deaths and Readmissions by Estimating Congestion âˆ—. <i>JACC: Heart Failure</i> , 2015, 3, 894-895.	1.9	7
492	Implications of serial measurements of natriuretic peptides in heart failure: insights from <sc>BIOSTAT&#x2013;CHF</sc>. <i>European Journal of Heart Failure</i> , 2020, 22, 1486-1490.	2.9	7
493	New data on soluble ACE2 in patients with atrial fibrillation reveal potential value for treatment of patients with COVID-19 and cardiovascular disease. <i>European Heart Journal</i> , 2020, 41, 4047-4049.	1.0	7
494	Geographical differences in heart failure characteristics and treatment across Europe: results from the BIOSTAT-CHF study. <i>Clinical Research in Cardiology</i> , 2020, 109, 967-977.	1.5	7
495	The Additive Prognostic Value of Serial Plasma Interleukin-6 Levels over Changes in Brain Natriuretic Peptide in Patients with Acute Heart Failure. <i>Journal of Cardiac Failure</i> , 2021, 27, 808-811.	0.7	7
496	Association of Early Blood Pressure Decrease and Renal Function With Prognosis in Acute Heart Failure. <i>JACC: Heart Failure</i> , 2021, 9, 890-903.	1.9	7
497	Clinical implications of low estimated protein intake in patients with heart failure. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2022, , .	2.9	7
498	Difference in long-term prognostic value of renal function between ischemic and non-ischemic mild heart failure. <i>International Journal of Cardiology</i> , 2006, 107, 73-77.	0.8	6
499	The <i>European Heart Journal</i> and the <i>European Journal of Heart Failure</i>: partners in scientific publishing. <i>European Journal of Heart Failure</i> , 2012, 14, 1075-1082.	2.9	6
500	The puzzle of kidney dysfunction in heart failure: an introduction. <i>Heart Failure Reviews</i> , 2012, 17, 129-131.	1.7	6
501	Risk-based evaluation of efficacy of rolofylline in patients hospitalized with acute heart failure â€” Post-hoc analysis of the PROTECT trial. <i>International Journal of Cardiology</i> , 2016, 223, 967-975.	0.8	6
502	Using matrix assisted laser desorption ionisation mass spectrometry (MALDI-MS) profiling in order to predict clinical outcomes of patients with heart failure. <i>Clinical Proteomics</i> , 2018, 15, 35.	1.1	6
503	Digital arterial pressure pulse wave analysis and cardiovascular events in the general population: the Prevention of Renal and Vascular End-stage Disease study. <i>Journal of Hypertension</i> , 2020, 38, 1064-1071.	0.3	6
504	Ethnic differences in atrial fibrillation among patients with heart failure in Asia. <i>ESC Heart Failure</i> , 2020, 7, 1419-1429.	1.4	6

#	ARTICLE	IF	CITATIONS
505	Variation in human herpesvirus 6B telomeric integration, excision, and transmission between tissues and individuals. <i>ELife</i> , 2021, 10, .	2.8	6
506	Whole blood transcriptomic profiling identifies molecular pathways related to cardiovascular mortality in heart failure. <i>European Journal of Heart Failure</i> , 2022, 24, 1009-1019.	2.9	6
507	High Angiotensin II Responsiveness is Associated with Decreased Endothelium-Dependent Relaxation in Human Arteries. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2005, 6, 145-150.	1.0	5
508	Plasma matrix metalloproteinase-9 and ACE-inhibitor-induced improvement of urinary albumin excretion in non-diabetic, microalbuminuric subjects. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2007, 8, 177-180.	1.0	5
509	Effect of Fosinopril Treatment on Serum C-Reactive Protein Levels in Patients With Microalbuminuria. <i>American Journal of Cardiology</i> , 2008, 102, 223-225.	0.7	5
510	Effects of Rosuvastatin on Coronary Flow Reserve and Metabolic Mismatch in Patients With Heart Failure (from the CORONA Study). <i>American Journal of Cardiology</i> , 2010, 105, 517-521.	0.7	5
511	Should erythropoietin treatment in chronic heart failure be haemoglobin targeted?. <i>European Journal of Heart Failure</i> , 2010, 12, 215-216.	2.9	5
512	The Angiotensin Receptor Neprilysin Inhibitor LCZ696 in Heart Failure with Preserved Ejection Fraction: A Phase II Randomised-Controlled Trial. <i>Journal of Cardiac Failure</i> , 2012, 18, 883.	0.7	5
513	Safety and clinical outcome of erythropoiesis-stimulating agents in patients with ST-elevation myocardial infarction: A meta-analysis of individual patient data. <i>American Heart Journal</i> , 2014, 168, 354-362.e2.	1.2	5
514	Long-term cardiac abnormalities after cranial radiotherapy in childhood cancer survivors. <i>Acta Oncologica</i> , 2015, 54, 515-521.	0.8	5
515	CUPID 2: A Phase 2b Trial Investigating the Efficacy and Safety of the Intracoronary Administration of AAV1/SERCA2a in Patients with Advanced Heart Failure. <i>Journal of Cardiac Failure</i> , 2015, 21, 939-940.	0.7	5
516	Associations between volume status and circulating microRNAs in acute heart failure. <i>European Journal of Heart Failure</i> , 2017, 19, 1077-1078.	2.9	5
517	A heart failure phenotype stratified model for predicting 1-year mortality in patients admitted with acute heart failure: results from an individual participant data meta-analysis of four prospective European cohorts. <i>BMC Medicine</i> , 2021, 19, 21.	2.3	5
518	Telomere length is independently associated with all-cause mortality in chronic heart failure. <i>Heart</i> , 2022, 108, 124-129.	1.2	5
519	Prevalence and predictive value of electrocardiographic abnormalities in pulmonary hypertension: evidence from the Pan-African Pulmonary Hypertension Cohort (PAPUCO) study. <i>Cardiovascular Journal of Africa</i> , 2017, 28, 370-376.	0.2	5
520	Pathophysiological pathways in patients with heart failure and atrial fibrillation. <i>Cardiovascular Research</i> , 2022, 118, 2478-2487.	1.8	5
521	Surrogate markers of gut dysfunction are related to heart failure severity and outcome from the BIOSTAT-CHF consortium. <i>American Heart Journal</i> , 2022, 248, 108-119.	1.2	5
522	Economic evaluation of valsartan in patients with chronic heart failure: results from Val-HeFT adapted to The Netherlands. <i>Journal of Medical Economics</i> , 2006, 9, 121-131.	1.0	4

#	ARTICLE	IF	CITATIONS
523	Vascular benefits of angiotensin receptor blockers. Expert Opinion on Investigational Drugs, 2007, 16, 987-997.	1.9	4
524	Heart Failure in the Young. Journal of the American College of Cardiology, 2013, 62, 1855-1856.	1.2	4
525	Are circulating relaxin levels related to pulmonary hypertension in patients with heart failure?. European Journal of Heart Failure, 2017, 19, 958-960.	2.9	4
526	Heart failure with mid-range ejection fraction: causes and consequences. European Journal of Heart Failure, 2018, 20, 660-662.	2.9	4
527	Proportional pulse pressure relates to cardiac index in stabilized acute heart failure patients. Clinical and Experimental Hypertension, 2018, 40, 637-643.	0.5	4
528	Is Time of the Essence? The Impact of Time of Hospital Presentation in Acute Heart Failure. JACC: Heart Failure, 2018, 6, 298-307.	1.9	4
529	Rapid right-sided deterioration in heart failure with preserved ejection fraction. European Heart Journal, 2019, 40, 699-702.	1.0	4
530	Potassium abnormalities in patients with heart failure from 11 Asian regions: insights from the ASIAN-HF registry. European Journal of Heart Failure, 2020, 22, 751-754.	2.9	4
531	Proenkephalin and the risk of new-onset heart failure: data from prevention of renal and vascular end-stage disease. Clinical Cardiology, 2021, , .	0.7	4
532	Assessment of Proximal Tubular Function by Tubular Maximum Phosphate Reabsorption Capacity in Heart Failure. Clinical Journal of the American Society of Nephrology: CJASN, 2022, 17, 228-239.	2.2	4
533	Transcatheter edge-to-edge repair of tricuspid regurgitation in the Netherlands: state of the art and future perspectives. Netherlands Heart Journal, 2022, 30, 393-399.	0.3	4
534	Biomarker changes as surrogate endpoints in early-phase trials in heart failure with reduced ejection fraction. ESC Heart Failure, 2022, 9, 2107-2118.	1.4	4
535	Heart failure medication: moving from evidence generation to implementation. European Heart Journal, 2022, 43, 2588-2590.	1.0	4
536	Review: The revised role of ACE-inhibition after myocardial infarction in the thrombolytic/primary PCI era. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2004, 5, 161-168.	1.0	3
537	Statins and Autonomic Function in Chronic Heart Failure. Cardiovascular Drugs and Therapy, 2005, 19, 167-168.	1.3	3
538	Serum Erythropoietin Levels and Infarct Size. Journal of the American College of Cardiology, 2006, 47, 468-469.	1.2	3
539	The <i>European Journal of Heart Failure</i> in 2010: current impact factor, time-to-first decision, and number of submissions. European Journal of Heart Failure, 2010, 12, 895-897.	2.9	3
540	Grading diastolic left ventricular function. European Journal of Heart Failure, 2011, 13, 698-699.	2.9	3

#	ARTICLE	IF	CITATIONS
541	The year in cardiology: heart failure 2014. <i>European Heart Journal</i> , 2015, 36, 421-424.	1.0	3
542	Pharmacotherapy for comorbidities in chronic heart failure: a focus on hematinic deficiencies, diabetes mellitus and hyperkalemia. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 1527-1538.	0.9	3
543	Fibroblast growth factor 23 mediates the association between iron deficiency and mortality in worsening heart failure. <i>European Journal of Heart Failure</i> , 2020, 22, 903-906.	2.9	3
544	Optimal carbohydrate antigen 125 cutpoint for identifying low-risk patients after admission for acute heart failure. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2021, , .	0.4	3
545	Perceived risk profile and treatment optimization in heart failure: an analysis from BIOlogy Study to Tailored Treatment in chronic heart failure. <i>Clinical Cardiology</i> , 2021, 44, 780-788.	0.7	3
546	HIGH SOLUBLE TRANSFERRIN RECEPTOR IN PATIENTS WITH SYSTOLIC HEART FAILURE: A MEASURE OF IRON DEFICIENCY AND A STRONG PREDICTOR OF MORTALITY. <i>Journal of the American College of Cardiology</i> , 2013, 61, E749.	1.2	2
547	TIMING AND CLINICAL PREDICTORS OF EARLY VERSUS LATE READMISSION AMONG PATIENTS HOSPITALIZED FOR ACUTE HEART FAILURE: INSIGHTS FROM ASCEND-HF. <i>Journal of the American College of Cardiology</i> , 2017, 69, 766.	1.2	2
548	Sense and Sensibility of the Use of NT-proBNP for Eligibility in Clinical Trials. <i>JACC: Heart Failure</i> , 2018, 6, 257-259.	1.9	2
549	Site enrollment rate, outcomes, and study drug effects in a multicenter trial. Results from RELAX-AHF. <i>International Journal of Cardiology</i> , 2018, 253, 91-96.	0.8	2
550	Should Enrichment With Natriuretic Peptide Levels Be Mandatory in Global Clinical Trials?. <i>JACC: Heart Failure</i> , 2020, 8, 369-371.	1.9	2
551	Effects of sodium-glucose cotransporter 2 inhibition with empagliflozin on potassium handling in patients with acute heart failure. <i>European Journal of Heart Failure</i> , 2021, 23, 1049-1052.	2.9	2
552	Prognostic Value of Pulse Pressure in Heart Failure. <i>Journal of Cardiac Failure</i> , 2007, 13, 694.	0.7	1
553	Effects of Eprosartan on Diastolic Function and Neurohormones in Patients with Hypertension and Diastolic Dysfunction. <i>Cardiovascular Drugs and Therapy</i> , 2010, 24, 33-40.	1.3	1
554	Novel biomarkers for prediction of poor treatment response in heart failure to guide therapy. <i>Lancet</i> , The, 2014, 383, S32.	6.3	1
555	The Fastest Way to the Failing Heart Is Through the Kidneys. <i>JACC: Heart Failure</i> , 2017, 5, 682-683.	1.9	1
556	Quantifying the HDL proteome by mass spectrometry: how many proteins truly associate with HDL? Reply. <i>European Journal of Heart Failure</i> , 2018, 20, 1077-1078.	2.9	1
557	Treating Heart Failure With Antihyperglycemic Medications: Is Now the Right Time?. <i>Circulation</i> , 2019, 139, 2383-2385.	1.6	1
558	Discussion forum response to Canepa et al. <i>European Heart Journal</i> , 2019, 40, 705-706.	1.0	1



#	ARTICLE	IF	CITATIONS
559	Approaches to statistical analysis of repeated echocardiographic measurements after myocardial infarction and its relation to heart failure: Application of a random-effects model. <i>European Journal of Heart Failure</i> , 2002, 4, 277-282.	2.9	0
560	Response to Letter Regarding Article, "Endogenous Erythropoietin and Outcome in Heart Failure". <i>Circulation</i> , 2010, 122, .	1.6	0
561	Trial data resolve gaps in evidence-based treatment. <i>Nature Reviews Cardiology</i> , 2013, 10, 67-68.	6.1	0
562	Considerable Regional Variation in AAV1 Neutralizing Antibodies and Its Consequences for a Multinational Clinical Trial of Gene Transfer for Advanced Heart Failure: The CUPID 2 Experience. <i>Journal of Cardiac Failure</i> , 2014, 20, S93.	0.7	0
563	Reply. <i>Journal of the American College of Cardiology</i> , 2014, 64, 1535-1536.	1.2	0
564	Lessons Learned and to Be Learned About the Use of N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure and Atrial Fibrillation. <i>Circulation: Heart Failure</i> , 2017, 10, .	1.6	0
565	Risk stratification in acute heart failure: reply. <i>European Journal of Heart Failure</i> , 2018, 20, 945-947.	2.9	0
566	Time to Revisit the Value of Urine Collections in Heart Failure. <i>JACC: Heart Failure</i> , 2019, 7, 392-393.	1.9	0
567	What is the added value of the waist-to-hip ratio on top of the BIOSTAT risk prediction model in patients with heart failure? Reply. <i>European Journal of Heart Failure</i> , 2019, 21, 132-133.	2.9	0
568	Effect Of Vericiguat In Victoria According To Guideline-directed Medical Therapy. <i>Journal of Cardiac Failure</i> , 2020, 26, 1108-1109.	0.7	0
569	Drug development in oncology and devices—lessons for heart failure drug development and approval? a review. <i>Heart Failure Reviews</i> , 2021, 26, 255-262.	1.7	0
570	Is There Any Interaction Between Sex and Renal Function Change During Hospital Stay in Patients Hospitalized With Acute Heart Failure?. <i>Journal of Cardiac Failure</i> , 2021, 27, 934-941.	0.7	0
571	Atrial function in paroxysmal AF patients with and without heart failure with preserved ejection fraction: data from the AF-RISK study. <i>American Heart Journal</i> , 2021, 244, 36-41.	1.2	0
572	Abstract 11150: Albuminuria in Heart Failure is More Strongly Associated with Markers of Congestion Than Renal Dysfunction. <i>Circulation</i> , 2021, 144, .	1.6	0
573	Abstract 11074: Worsening Renal Function in Acute Heart Failure in the Context of Diuretic Response. <i>Circulation</i> , 2021, 144, .	1.6	0
574	128€fClinical impact of changes in mitral regurgitation severity after optimization of medical therapy in heart failure: insights from BIOSTAT-CHF. <i>European Heart Journal Supplements</i> , 2021, 23, .	0.0	0
575	Risk factors for the development of heart failure in patients with or without prior myocardial infarction. <i>European Journal of Heart Failure</i> , 2022, 24, 985-987.	2.9	0
576	Abstract 12543: Limited Blood Biomarker Changes After Reverse Remodelling: A Markers and Response to CRT (Marc) Substudy. <i>Circulation</i> , 2021, 144, .	1.6	0